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 Diabetes affects 25.8 million people in the United States and its prevalence is 
expected to triple in the next 20 years. Diabetic retinopathy (DR) affects nearly 30% of 
people with diabetes and is the leading cause of blindness in the working-age population. 
Current treatments for DR improve vision in only a minority of patients, and carry 
significant risks. This work advances a new approach that works by reversing retinal 
vascular damage and restoring normal perfusion to improve vision in this condition.  
Chapter 1 reviews the epidemiology, pathophysiology, and current standards of 
therapy for diabetic retinopathy. The roles of vascular maturation factor Angiopoietin-1 
(Ang1) and its receptor Tie2 are introduced.  
Chapter 2 describes the development of an improved method for visualization of 
leukocytes in the diabetic mouse retina, which was critical for studies in this dissertation 
and broadly applicable to fields studying leukocyte endothelial interaction and 
inflammation.  
Chapter 3 focuses on the studies describing prevention of neurovascular 
dysfunction in diabetic retinopathy achieved by treating diabetic mice with gene therapy 
expressing COMP-Ang1. This chapter further details the studies performed to reverse 
diabetic retinopathy with a combination therapy consisting of endothelial colony-forming 
cells (ECFCs) and COMP-Ang1. We demonstrated that COMP-Ang1 enhanced the 
  
 
vasculogenic capabilities of ECFCs leading to increased integration into the diabetic 
retina and preservation of visual function in mice with advanced diabetic retinopathy.  
Chapter 4 represents my contributions toward the understanding of how targeting 
alternative VEGF receptor 2 splicing can suppress hemangiogenesis and 
lymphangiogenesis in the retina and choroid. This work was published in the FASEB 
journal in 2013.  
Chapter 5 describes my work published in PLoS ONE describing suppression of 
both tumor and ocular neovascularization, wherein we used morpholinos to increased 
soluble VEGF receptor 1.  
Chapter 6 concludes this work by recapping how the work accomplished in this 
dissertation built off of previous discoveries.  
 The Appendix describes studies initiated to test the effects of COMP-Ang1 in an 

















I wish to dedicate this work to Lindsay, Maggie, and Bennett for sticking with me. 
Secondly, I wish to dedicate this work to an outstanding mentor who has done more to 
inspire me and shape my outlook than anyone else. Thank you, Bala, for your 






























LIST OF TABLES ……………………………………………………………….. ix 
LIST OF FIGURES ……………………………………………………………….       x 
ACKNOWLEDGEMENTS……………………………………………………….   xii 
Chapters 
1. AN INTRODUCTION TO DIABETIC RETINOPATHY AND COMP-ANG1.    1 
1.1 Clinical features of diabetic retinopathy………………………………. 2 
1.2 Epidemiology..…………………………………………………............ 4 
1.3 Cellular mechanisms for diabetic retinopathy.………………………… 6 
1.4 Molecular mechanisms in diabetic retinopathy.……………………….. 7 
1.5 Pharmacotherapies for diabetic retinopathy…..……………………….. 10 
1.6 The angiopoietin-1 Tie2 system…………..…..……………………….. 12 
1.7 Development of COMP-Ang1…………….…..……………………….. 13 
1.8 Stem cell therapy of the diabetic retina…...…..……………………….. 14 
1.9 AAV2 mediated gene therapy ………………..……………………….. 16 
1.10 Discussion………………….………………..……………………….. 17 
1.11 References………………………………………………………………. 18 
 
2.   ACRIDINE ORANGE LEUKOCYTE FLUOROGRAPHY IN MICE……….. 32 
   
2.1 Introduction……..………………………….………………………….. 33 
2.2 Materials and supplies…………………………………………………. 34 
2.3 Detailed methods………………………………………………………. 34 
2.4 Potential pitfalls and troubleshooting………………………………….. 35 
2.5 Discussion…………………………………………………………….... 36 
2.6 References………………………………………………………………..  37 
 
3. COMP-ANG1 AND ENDOTHELIAL COLONY-FORMING CELLS  




3.1 Abstract.....……………………………………….………………………  39 
3.2 Introduction………………………………………………………………    39 
3.3 Materials and methods..………………………………………………….    43 
3.4 Results……………………………………………………………………    49 
3.5 Discussion………………………………..………………………………    57 
3.6 Acknowledgments………………………………………………………..    61 
3.7 References………………………………………………………………..    61 
 
4. DUAL SUPPRESSION OF HEAMANGIOGENESIS AND LYMPHANGIO-
GENESIS BY SPLICE-SHIFTING MORPHOLINOS TARGETING VASCULAR 
ENDOTHELIAL GROWTH FACTOR RECEPTOR 2 (KDR)…..……………..    67 
 
4.1 Introduction..……………………………………….…………………….    68 
4.2 Materials and methods…………………………………………………...    69 
4.3 Results…...……………………………………………………………….    71 
4.4 Discussion…………..…………………………………………………....    75 
4.5 References………………………………………………………………...   76 
 
5. MORPHOLINO-MEDIATED INCREASE IN SOLUBLE FLT-1 EXPRESSION 
RESULTS IN DECREASED OCULAR AND TUMOR  
NEOVASCULARIZATION …………………………………………………….   78 
 
5.1 Introduction..……………………………………….…………………….   79 
5.2 Results……………………………………………………………………   80 
5.3 Discussion…………….…………………………………………………    83 
5.4 Materials and Methods..……………………………………..…………...   85 
5.5 References………………………………………………………………..   86 
 
6. CONCLUDING REMARKS AND FUTURE DIRECTIONS…………………..   88 
 
6.1 References..……………………………………….……………………...   92 
 
APPENDIX: COMP-ANG1 IN THE PROTECTION AGAINST CENTRAL RETINAL  







LIST OF TABLES 
 
2.1. Leukocyte velocity in C57Bl6/J mice is given in each area of the vascular 
tree…………………………………………….………………………………………. 35 
 










LIST OF FIGURES 
 
1.1. A healthy retina (fundus photo, left) is compared to a retina with mild diabetic 
retinopathy (middle) and proliferative diabetic retinopathy (right) ………………… 3 
 
1.2 A schematic depicting damage caused by hyperglycemia to the retinal 
vasculature…………………………………..………………………………………... 13 
 
1.3 A schematized view of the potential for Tie2 modulation in the diabetic retina.. 17 
 
2.1 Graph demonstrating leukocyte velocity in each segment of the vascular tree… 35 
 
2.2 The number of rolling leukocytes counted over a five minute observation period 
following acridine orange administration………….………………………………… 35 
 
2.3 Leukocyte extravasation was seen 30 min after acridine orange administration 
with the scanning laser ophthalmascope and was confirmed with confocal 
microscopy…………………………….……………………………………………....  36 
 
2.4 To determine whether acridine orange altered leukocyte endothelial interactions, 
human leukocytes were rolled across a human retinal microvascular endothelila cell 
monolayer at a constant rate…………………………………...……………………..   36 
 
3.1 COMP-Ang1 mitigates diabetic retinal capillary dropout………………………  50 
 
3.2 COMP-Ang1 enhances barrier function and reduces ischemia………...….……  52 
 
3.3 COMP-Ang1 prevents diabetes-induced retinal ganglion cell layer degeneration 
and stabilizes visual function…………………………………………………... 55 
 
3.4 COMP-Ang1 enhances ECFC engraftment into the diabetic retina and prevents 
further visual decline…………………………………………………………..    58 
 
4.1 KDR_MOe13 decreased mbKDR mRNA and increases sKDR mRNA………..  71 
 
4.2 KDR_MOe13 decreases mbKDR protein and increases sKDR protein.….……   72 
 
4.3 Polyadenylation signal induced by KDR_MOe13 was the same polyadenylation 
signal as in endogenous sKDR found in human cornea..…………………….... 73 
  
 
4.4 moVEGFR2_MOe13 suppresses experimental neovascularization and   
lymphangiogenesis in mice...…………………………………………………..   74 
 
4.5 moKDR_MOe13 suppresses graft rejection in mouse corneal transplantation…  75 
 
5.1 VEGFR1_MOe13 localizes to the nucleus and increases sFLT-1 expression in 
human endothelial vein cells (HUVEC)………………………………………..   81 
 
5.2 VEGFR1_MOe13 increases sFLT and decreases mbFLT-1 mRNA in MCF-7 and 
MBA-MD-231 breast adenocarcinoma cell lines……………………..….……   82 
 
5.3 VEGFR1_MOe13 inhibits laser-induced CNV in vivo………………………..    83 
 
5.4 RNAi targeting sFlt-1 rescues the neovascular phenotype response to laser 
injury………………………………………………………………………….…  83 
 
5.5 Intra-tumoral VEGFR1_MOe13 injection results in regression of established 
MBA-MD-231 human breast adenocarcinoma xenograft tumors and decreased 
tumor vascularity…………………………………….....…………………….... 84 
 
A.1 Fluorescein angiography confirms the presence of CRAO two hours after laser 
treatment………………………………………………………………………..   98 
 
A.2 Retinal cross sections taken three weeks after CRAO show COMP-Ang1 
preserved the ganglion cell marker TuJ1, white (a) and neural progenitor marker 
Sox2, white (b)…………………..……………...……………………..….……   99 
 
A.3 Functional data showing COMP-Ang1 protects against prolonged visual tracking 
impairment……………………………………………………………………..  100 
 
A.4 Mice wre treated after CRAO with COMP-Ang1 protein or PBS..…………..   101 
 















 I must acknowledge the longsuffering and patience of my family for enduring 
my extended absences as I sometimes lost myself in lab. Importantly, I must express my 
extreme gratitude to my mentor, Dr. Bala Ambati. Bala encompasses all aspects of a 
mentor, academically, clinically, and in his humanitarian efforts. He has singularly 
shaped my view of health care, the current research environment, and what it takes to be 
a person who happens to be a physician, instead of the other way around. In total, he has 
inspired me to chase the dream and become a physician-scientist. This dissertation will 
serve as only the first step in my progress.   
 I would also like to recognize the programs that have supported me along the 
way. The Interdepartmental Program In Neuroscience has supported me since I joined 
in 2010, especially Tracy Marble, who keeps me in track. The MD-PhD program at the 
University of Utah has been an exceptional place to grow as a person, build lasting 
friendships, and commiserate with colleagues as we develop. I would especially like to 
thank Janet Bassett for her encouragement and kindness.   
 


































   2 
 
This chapter will introduce the concepts behind the pathogenesis of diabetic 
retinopathy and the angiopoietin-Tie2 signaling pathway. The concepts of endothelial 
progenitor cells and vector gene therapy will be introduced. Finally, the hypothesis that 
gene therapy with COMP-Ang1 plus endothelial progenitor cells can prevent and reverse 
the damage caused by diabetic retinopathy will also be introduced.  
 
 
1.1 Clinical features of diabetic retinopathy 
 
 Diabetic retinopathy (DR) is a neurovascular disease affecting patients with long 
standing diabetes (e.g., elevated blood glucose levels) and is the leading cause of 
blindness in the working-age population in the US (Frank, 2004; R. Klein, Knudtson, 
Lee, Gangnon, & Klein, 2008). For the first 10 – 15 years of diabetes, no clinically 
apparent signs of DR manifest in the retina, making it an insidious and chronic disease.   
Physicians classify DR based on the severity of symptoms presented during a 
fundus exam (Wilkinson et al., 2003). Mild DR presents with micro-aneurysms that can 
appear and disappear over time; however, patients can still maintain 20/20 visual acuity, 
delaying them from seeking treatment. Moderate DR presents with more red blood cell 
leakage (hemorrhage), plasma leakage (edema), and lipid leakage (exudate) (see Figure 
1.1). Clinically significant macular edema (CSME) can also occur if retinal thickening 
occurs within 500 µm of macula (Sander, Hamann, & Larsen, 2008). Diabetics with mild 
to moderate retinopathy are followed with annual eye exams to monitor the progression 
of the disease (Aiello et al., 2010).  
 Patients are diagnosed with severe DR if there is either retinal hemorrhage in four 
quadrants, venous bleeding in two quadrants, or intraretinal microvascular abnormalities  






in one quadrant—the so-called 4:2:1 rule (R. Klein, Klein, & Moss, 1992). These patients  
require eye exams every four months. Proliferative DR is characterized by blood vessel 
growth into the vitreous and requires immediate treatment, as this is a sight-threatening 
condition.  
Risk factors DR progression include duration of poor glucose control, poor lipid 
levels, and poor blood pressure control (Yau et al., 2012). After 20 years of poor 
glycemic control, 100% of patients initially diagnosed under the age of 30 will develop 
DR, with half of those patients developing the serious complications related to 
proliferative DR (R. Klein, Klein, Moss, Davis, & DeMets, 1984; Sjølie & Green, 1987).  
As such, this disease has a higher prevalence in patients with type 1 diabetes because 
these patients are typically diagnosed at a younger age (R. Klein, Knudtson, Lee, 
Gangnon, & Klein, 2009).  
 Observation of patients with DR is accomplished with a fundus exam, fluorescein 
angiography, and optical coherence tomography (OCT). OCT is used for fast, non-
Figure 1.1: A healthy retina (fundus photo, left) is compared to a retina with mild 
diabetic retinopathy (middle) and proliferative diabetic retinopathy (right). Areas of 
vascular leak and hemorrhage are evident as small red spots and yellow exudate in the 
mild diabetic retinopathy fundus exam (middle) and pre-retinal hemorrhage is evident 
in the proliferative diabetic retinopathy fundus exam (right). All photos used with 
permission and courtesy of Dr. Bala Ambati.   
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invasive visualization of the retina to assess traction and neuronal changes and identify 
any diabetic macular edema (DME). Functional examinations of the diabetic retina 
include electro-retinal grams (ERGs) and visual acuity (VA) testing. Changes in 
oscillatory potentials (found with ERGs) and contrast sensitivity (determined by VA 
testing) are some of the earliest indications of DR (Bresnick & Palta, 1987; Bresnick, 





Diabetes currently affects more than 371 million people worldwide—a number 
that is projected to increase to over 500 million by 2030 (J. E. Shaw, Sicree, & Zimmet, 
2010). DR affects 35% of all diabetic patients with 7% experiencing proliferative DR and 
another 7% with diabetic macular edema (DME) (Yau et al., 2012). Currently, over 130 
million people are at risk of losing their vision due to diabetic complications (Ko et al., 
2012).   
Global risk factors are largely similar (O. S. Huang et al., 2010). Diabetes 
duration—measured by glycosylated hemoglobin (HbA1c)—and high blood pressure are 
consistently elevated in most studies of DR (Yau et al., 2012). The Diabetic 
Complications Control Trial showed that hyperglycemia is responsible for many diabetic 
pathologies and tight glucose control (defined as HbA1c < 7%) leads to a 76% reduction 
in DR (“The effect of intensive treatment of diabetes on the development and progression 
of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control 
and Complications Trial Research Group,” 1993). Reducing HbA1c by 1% lessened the 
rate of progression of DR by 40%. Tight glycemic control even resulted in a 10-year 
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“memory effect,” where after a one-year period of tight glucose control patients were 
allowed to return to higher HbA1c levels and still experienced beneficial effects from 
glycemic control ten years afterwards (White et al., 2008). This metabolic memory 
phenomenon could be from the effects of glycemic status on gene expression or advanced 
glycation end-product (AGE) formation. However, tight glucose control is only achieved 
by a small number of patients and glycemic control itself is not without drawbacks. It 
should be noted that tight blood glucose control (6% HbA1c) leads to an increase in all-
cause mortality (A. T. C. C. R. I. D. S. Group et al., 2008).  
 Control of other risk factors has been met with only modest success. (A. S. 
Group, Cushman, et al., 2010a; B. E. Klein, Klein, Moss, & Palta, 1995; Wong et al., 
2009). For example, patients with high cholesterol had more macular lipid deposits and 
treatment with fenofibrates and statins helped reduce retinopathy endpoints, but not to 
same degree as glycemic control (Chew et al., 1996). Blood pressure control exerts only a 
modest effect on the progression of DR (A. S. Group, Ginsberg, et al., 2010b; A. S. 
Group, Group, et al., 2010c; Stratton et al., 2001).  
Finally, DR awareness is very low; up to 80% of people with DR are unaware 
they have the disease (Bressler et al., 2014; O. S. Huang et al., 2009). In light of the 
difficulties patients face in controlling their blood sugar, further treatments for DR are 
required. Development of new treatments requires an understanding of the 
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1.3 Cellular mechanisms for diabetic retinopathy 
 
 Hemodynamic, metabolic, and genetic alterations occur in diabetes. Early stages 
can be divided into three pathologic components: 1) capillary degeneration and non-
perfusion, 2) vascular permeability and edema, and 3) neuroglial dysfunction and 
degeneration (Forbes & Cooper, 2013). Targeted therapies exist or have been 
investigated to stymie capillary degeneration. Similarly, many therapies have been 
developed (experimentally) to reduce vascular permeability and capillary degeneration. 
Far fewer potential therapeutics target neuroglial dysfunction.  
The cellular contribution to DR can be divided between factors within and 
without the retina. Within the retina, the vascular component, glial cells, microglia, and 
neural cells (especially photoreceptors) may contribute to pathology (Li et al., 2012). 
Most of the reactive oxygen species (ROS) in the retina originate within photoreceptors 
(PR), mainly in the outer segments (Du, Veenstra, Palczewski, & Kern, 2013). Diabetes 
alters the metabolic phenotype of PRs, resulting in ischemia that mediates pro-
inflammatory changes in the vasculature. Capillary nonperfusion, due to platelet 
aggregation, leukocyte adhesion, and intercellular adhesion molecule (ICAM) expression 
can lead to hypoxia and vascular endothelial growth factor (VEGF) release (Adamis, 
Joussen, et al., 2001a). The same processes that lead to neovascularization (e.g., VEGF) 
also lead to leaky vessels, which can gain traction on the vitreous and cause retinal 
detachment. In severe cases of DR neovascularization of the iris can occur, which is very 
painful for the patient (Fernández-Vigo, Castro, & Macarro, 1997).  
Vascular disruptions are indications of pericyte loss. Pericytes are vascular 
support cells found abundantly in the retina at a 1:1 ratio with the endothelial cells 
   7 
 
(Mizutani, Kern, & Lorenzi, 1996). Pericytes provide structural and trophic support to the 
underlying endothelium (Romeo, Liu, Asnaghi, Kern, & Lorenzi, 2002) and dropout has 
been associated with increased formation of microaneurysms.  
Outside the retina, leukocytes are the predominate pathological drivers of DR 
(Joussen et al., 2004). Elimination of inflammatory proteins in bone marrow derived cells 
results in retinal sparing from diabetic-induced damage. Leukocytes from diabetic 
patients are cytotoxic to retinal endothelial cells in vitro (Li et al., 2012). Vascular 
endothelial cells of the retina respond to diabetes by increasing intercellular adhesion 
molecules (ICAM) expression, inducing leukocyte adhesion to the vascular wall. These 
leukocytes can occlude capillaries resulting in retinal hypoxia. Diminishing endothelial-
leukocyte interaction is an attractive therapeutic approach.  
 
 
1.4 Molecular mechanisms in diabetic retinopathy 
 
Hyperglycemia results in repeated acute changes in cellular metabolism and 
cumulative long-term changes in stable macromolecules. These changes have reciprocal 
effects.  
Some of the key biochemical changes sustained from diabetes include formation 
of advanced glycation end products (AGES), increased flux through the polyol pathway, 
activation of the PKC pathway (which increases VEGF), an accelerated inflammatory 
response with increased inflammatory cytokine production, and enhanced reactive 
oxygen species (ROS) (Forbes & Cooper, 2013). These biochemical features lead to 
functional changes such as decreased blood flow, loss of tight junctions, and permeability 
changes. Finally, structural changes occur: pericyte, endothelial, and ganglion cell loss, 
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with accompanying growth factor alteration, vessel occlusion, and ultimately neovascular 
DR as a result of these biochemical changes. 
Aldose reductase, found in pericytes, can reduce glucose to sorbitol. However, the 
high levels of glucose in the diabetic retina result in accumulation of sorbitol in the 
pericytes causing osmotic pressure, swelling, and eventually death of pericytes. This is 
referred to as increased flux through the polyol pathway.  
Oxidative stress—defined as an imbalance between ROS and the antioxidant 
species in a system—is a major underlying problem in DR. It can damage DNA, fatty 
acids, and enzymes (Xie et al., 2008). Lipid peroxidation, a consequence of oxidative 
stress, damages the cellular membrane leading to cellular injury. Enzymes can be 
inappropriately activated or inactivated through thiol oxidation and carbonyl formation. 
Hyperglycemia eventually leads to decreased superoxide dismutase (SOD), a key enzyme 
responsible for combatting ROS. Finally, ROS can increase caspase numbers, leading to 
apoptosis of retinal cells including pericytes, endothelial cells, and ganglion cells. 
Furthermore, glucose reacts with H2O2 in the presence of iron and copper to form 
radicals, which can impair mitochondrial electron transport.  
Inflammatory cytokines (like TNF-α and IL1-β) are up regulated in diabetes, 
while anti-inflammatory cytokines are down regulated. Inflammation can damage the 
mitochondria and exacerbate ROS production. Elevated levels of activated leukocytes 
have been noted after one week of diabetes (Joussen et al., 2004).  In diabetics, 
leukocytes have increased CD11b, CD18, and ICAM-1 circulating in the serum, which 
increases their reactivity (Fasching et al., 1996; Limb, Webster, Soomro, Janikoun, & 
Shilling, 1999; Muni et al., 2013). Leukostasis is associated with capillary occlusion and 
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ROS-mediated cell death, which further amplifies the local inflammatory response. 
Experimentally, reduced leukocyte entrapment often leads to reduced progression of DR. 
Pro-inflammatory cytokines are associated with progression of DR and up-regulated 
factors include Ang2, MMP, TNF-α, CCl2, and the Kallikrein-kinin system. Activation 
of microglia also plays a role in the pathogenesis of DR as microglia increase nitric oxide 
(NO) and other inflammatory cytokines.  
AGEs occur due to the overwhelming amount of a substrate, i.e., glucose, non-
enzymatically binding to proteins. In fact, the nonenzymatic glycosylation of hemoglobin 
(HbA1c) is the basis for measuring the severity of diabetes.  AGEs are found in the 
diabetic microenvironment and alter the normal homeostasis of the cell (Goldin, 
Beckman, Schmidt, & Creager, 2006; Singh, Barden, Mori, & Beilin, 2001).  
The pathophysiology of DR is often described as vascular in nature. Pericytes are 
particularly sensitive to increased flux through the polyol pathway in addition to damage 
from AGEs. Loss of pericytes results in diminished structural and trophic support to the 
endothelium. Endothelial cells ultimately become weaker, resulting in microaneurysms 
and endothelial apoptosis. Lack of endothelial cells decreases delivery of oxygen and 
essential nutrients to the retina resulting in ischemia-driven VEGF secretion. Excessive 
VEGF secretion results in increased vascular permeability, immature neovascularization, 
and increased inflammation. Preventing vascular disturbances could have beneficial side 
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1.5 Pharmacotherapies for diabetic retinopathy 
 
 With the understanding that the foundation of treatment for diabetic eye disease is 
systemic glucose control, pharmacotherapeutic strategies still must be pursued because 
many patients are not able to achieve targeted systemic control. Current first-line clinical 
therapies for DR include pan-retinal laser photocoagulation (PRP) and VEGF inhibition 
(Diabetic Retinopathy Clinical Research Network et al., 2012). The rationale behind both 
of these treatments is to reduce VEGF levels in the retina.   
Multiple VEGF inhibitors are used in the treatment of DR but only one, 
ranibizumab, is FDA approved for DME. Because the half-life of anti-VEGF agents is 
only 8-9 days in the eye, treatments consist of monthly intraocular injections and are 
accompanied by PRP to treat proliferative DR. While treatment intervals can be reduced 
after one year, regular intravitreal injections are still required. PRP improves tight 
junctions in the retina, as the grid laser stimulates retinal pigmented epithelial (RPE) cells 
to phagocytose hard exudates. Laser treatment is considered the gold standard of 
proliferative DR and is used as an adjunct to anti-VEGF therapies in other forms of DR, 
including macular edema.  
VEGF is up regulated in DME and numerous trials have shown anti-VEGF is 
beneficial; however, despite treatments that reduce intraocular VEGF levels the retinal 
vasculature does not always return to normal (Brown et al., 2013; Nguyen et al., 2012; 
2010). Anti-VEGF drugs are more efficacious in proliferative DR, but response of DME 
to anti-VEGF agents is variable (Mitchell, Wong, Diabetic Macular Edema Treatment 
Guideline Working Group, 2014). Once anti-VEGF therapy is stopped, the edema 
resurfaces. Thus, the effects of anti-VEGF therapy on DME are transient at best, 
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especially since 50% of patients still have DME after a year of treatment. Furthermore, 
overuse of anti-VEGF medications could be toxic to the eye as it has been shown that 
VEGF is good for retinal health (Quaggin, 2012; Sivaskandarajah et al., 2012).  
Switching to intravitreal steroid as a way to reduce inflammation is a second line 
of therapy, but visual acuity worsens after a year of treatment, due to increased cataract 
formation (Elman et al., 2011; Campochiaro et al., 2012, 2011). Currently, intraocular 
implants do exist for long-acting steroids (Ciulla, Harris, McIntyre, & Jonescu-Cuypers, 
2014).  
PRP is the current standard treatment for proliferative DR (Bressler, Beck, & 
Ferris, 2011). PRP reduces DR by increasing O2 availability and decreasing VEGF 
production. However, some patients treated with PRP still have persistent 
neovascularization.  Although a more invasive and riskier surgery, early vitrectomy has 
proven beneficial for advanced active proliferative DR in young patients with long 
standing DR.  
PRP is a brutal effort to reduce VEGF by eliminating parts of the retina that 
respond to hypoxia by secreting VEGF. This results in diminished night vision and poor 
peripheral vision in an attempt to salvage central vision. Current antibody injection 
therapies against VEGF are potent, selective, and administered at high doses, with all 
trials showing similar responses. However, the fact that only 50% of treated eyes respond 
to anti-VEGF therapy indicates that there are most likely VEGF-independent pathways 
responsible for some pathogenesis in DR. Targeting a new pathway in the diabetic retina 
is necessary to overcome the current treatment plateau.  
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1.6 The angiopoietin-1 Tie2 system 
 
 During physiologic homeostasis, vasculature stabilization is mediated, in part, 
through angiopoietin-1 (Ang1) (Thurston et al., 2000). Ang1 helps maintain blood vessel 
quiescence by binding the endothelial tyrosine kinase with Ig and epidermal growth 
factor homology domain receptor 2 (Tie2) (Asahara et al., 1998; Partanen et al., 1992). 
Both Ang1 and Tie2 are necessary for fetal development (Suri et al., 1996; Takakura et 
al., 1998). The effects of Tie2 phosphorylation/activation include decreased leakage, 
leukocyte adhesion, and apoptosis (Adamis, Joussen, et al., 2001a; Joussen et al., 2004; 
Thurston et al., 2000).  
Tie2 activates mDia to sequester Src, which mediates VEGF-induced 
internalization of vascular endothelial cadherin (VE-cadherin) (Gavard, Patel, & Gutkind, 
2008). VE-cadherin is a calcium-dependent transmembrane protein in the adherens 
junction between endothelial cells that promotes vascular integrity and decreases vascular 
permeability (Carmeliet et al., 1999). By preventing Src from phosphorylating VE-
cadherin, Tie2 results in greater junctional integrity between endothelial cells and 
decreased leakage (see Figure 1.2).  
Tie2 also increases PI3K/Akt signaling, leading to inhibition of caspase 9 and 
other apoptotic factors, thus promoting endothelial cell survival (Papapetropoulos et al., 
2000). Ang1 exhibits its anti-inflammatory effects through Tie2 by blocking nuclear 
factor kappa b (NFkB) through ABIN2. Inhibition of NFkB prevents ICAM and integrin  
signaling used in leukocyte recruitment (Hughes, Marron, & Brindle, 2003; Jeon et al., 
2003; Tadros, Hughes, Dunmore, & Brindle, 2003). Patients with DR have decreased 
vitreous levels of Ang1 (J. I. Patel, Hykin, Gregor, Boulton, & Cree, 2005). Restoration  







of Ang1 signaling could serve as a complimentary strategy to VEGF inhibition in the 
treatment of DR.   
 
1.7 Development of COMP-Ang1 
Ang1 structure contains three basic parts: a short N-terminal domain which 
superclusters the protein into variably sized multimers, a central coiled-coil domain 
responsible for oligimerizing the individual proteins, and a C-terminal fibrinogen-like 
domain responsible for binding the receptor (S. Davis et al., 2003; Procopio, Pelavin, 
Lee, & Yeilding, 1999). However, the coiled-coil domain and the N-terminal 
superclustering region result in protein aggregation and insolubility, making it difficult to 
Figure 1.2: A schematic depicting damage caused by hyperglycemia to the retinal 
vasculature. Shown on the left is a normal retinal capillary composed of two 
endothelial cells and a supporting pericyte. Pericytes secrete Ang1, which supports 
endothelial health and VE-cadherin stabilization. During diabetes, pericytes and 
Ang1 are lost, resulting in VE-cadherin internalization and degradation, increased 
vascular hyperpermeability, and increased leukocyte adhesion (inflammation). 
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work with in a pharmacological setting (Maisonpierre et al., 1997). Cartilage oligo matrix 
protein (COMP) Ang1 was developed to overcome these limitations. By replacing the 
superclustering region of the N-terminus and the coiled-coil domain with COMP, 
researchers were able to generate a soluble yet stable and potent version of the native 
Ang1 protein (Cho et al., 2004). COMP-Ang1 has been shown to reduce neurovascular 
deficits in ischemic stroke, diabetic nephropathy, and wound healing, but has yet to be 
tested in DR (Cho et al., 2006; S. Lee et al., 2007; Shin et al., 2010).  
 
 
1.8 Stem cell therapy of the diabetic retina 
 
Stem cell therapy for DR has recently gained traction (Bhatwadekar, Shaw, & 
Grant, 2010). There are currently almost 2,000 clinical trials involving bone marrow stem 
cells for the treatment of DR and age-related macular degeneration. Endothelial 
progenitor cells (EPCs), which are found circulating in the serum, can inhibit damage and 
stimulate repair in the diabetic retina (Busik et al., 2009; “Circulating mononuclear 
progenitor cells: differential roles for subpopulations in repair of retinal vascular injury,” 
2013).  
The term EPC encapsulates a diverse group of CD34+ cell-types with myeloid, 
haematopoietic or endothelial characteristics (Afzal et al., 2007; O'Neill et al., 2012; Stitt 
et al., 2011). Adipocyte-derived EPCs have been able to generate pericytes or endothelial 
cells, depending on the mode of delivery (Traktuev et al., 2008). EPC delivery has 
reduced leakage and improved ERG in animal models of ischemic retinopathy (Ritter et 
al., 2006). However, bone marrow-derived EPCs are impacted by the biochemical 
alterations of diabetes, which could play a role in faulty repair of the retinal vasculature 
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(Yellowlees Douglas et al., 2012). Serum levels of EPCs respond to, and have been used 
as biomarkers of, various diseases including diabetes, hypertension, coronary artery 
disease, smoking, and aging (Brunner et al., 2011). Following the levels of EPCs in the 
systemic circulation has even proved a useful predictor of diabetic complications. 
Patients with DR have decreased levels of EPCs, that also demonstrate a reduced ability 
to differentiate and increased production of ROS. Diabetic EPCs do not respond to 
hypoxia and exhibit a decreased paracrine ability to induce vasodilatation in vessels 
(Jarajapu et al., 2014). Development of therapies that a) enhance endogenous EPC 
activity in diabetic patients or b) replace diabetic EPCs with nondiabetic, and therefore 
fully functioning, EPCs would be a great boon to DR therapy.  
A unique EPC subtype, known as endothelial colony-forming cells (ECFCs, also 
known as outgrowth endothelial cells (OECs)), has been shown to encompass true 
endothelial progenitors that fully integrate into blood vessels and serve to regenerate 
damaged vasculature in the ischemic retina (Medina, O'Neill, Humphreys, Gardiner, & 
Stitt, 2010a), as well as other ischemic models (Alphonse et al., 2014; Critser & Yoder, 
2010). Recently, ECFCs generated from cord blood have been able to generate both 
endothelial cells and pericytes (Medina, O'Neill, Humphreys, Gardiner, & Stitt, 2010a). 
These cells were pulled from the mononuclear layer and enriched by collagen adherence 
in vitro, and demonstrated the capability to form vasculature in a mouse. More 
importantly, they were even able to assimilate into a hypoxic retina (Medina, O'Neill, 
Sweeney, Guduric-Fuchs, Gardiner, Simpson, et al., 2010b). ECFCs represent a distinct 
subtype of endothelial progenitor cell with the potential to act as a cellular therapeutic in 
vascularizing the ischemic retina (Medina, O'Neill, O'Doherty, Wilson, & Stitt, 2012).   
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1.9 AAV2 mediated gene therapy 
Due to the chronic nature of diabetes, repeated injections into the eye of 
pharmacotherapies are often required. The drawbacks to this delivery method are readily 
evident, but also include risks of infection, retinal damage, and uveitis (Jager, Aiello, 
Patel, & Cunningham, 2004). In order to gain long-term expression of any protein of 
interest, gene therapy is an attractive option. The concept behind gene therapy is to 
replace the deficient gene responsible for disease progression with a normally functioning 
gene. This can be accomplished by packaging a replication deficient and non-
inflammatory viral construct with a plasmid encoding the gene of interest. Adeno-
associated virus (AAV) has emerged as a leading candidate vector for gene therapy trials 
in patients with retinal pathologies (Maguire et al., 2008). Currently, most gene therapy 
approaches in the retina have focused on inherited genetic diseases like Lebers 
Congenital Amourosis (LCA) using AAV to replace the deficient copy of the RPE65 
gene (Maguire et al., 2008). As these clinical trials have progressed, it has become 
evident that AAV therapy in the eye is safe and effective at delivering gene products to 
the retina (Colella & Auricchio, 2012; Jacobson et al., 2012). A wide variety of AAV 
serotypes exist, each with its own tropism. AAV serotype 2 (AAV2) is trophic for post-
mitotic cells and, when delivered as an intravitreal injection, remains in the inner retina 
(Yin et al., 2011). A single intravitreal injection of AAV2 has been shown to last in the 
retina for as long as two years and results in expression of product in the ganglion cell 
and inner plexiform layers. As patients with DR have chronically low levels of Ang1 due 
to pericyte loss, replacing Ang1 with gene therapy could serve as a way to mitigate the 
risks of regular intravitreal injections. This project aimed to promote constitutive 
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expression of COMP-Ang1 in a mouse model of diabetic retinopathy. As diabetic 
vascular damage is also located in the inner retina, AAV2 was the most appropriate 





With this basic understanding of the enormity of the situation, the 
pathophysiology of diabetic retinopathy, and the potential for COMP-Ang1 to act as a 
therapeutic, this dissertation will focus on the effects of early AAV2-meditaed COMP-
Ang1 administration to diabetic mice in an attempt to prevent neurovascular dysfunction 
and combination therapy of both COMP-Ang1 and ECFCs delivered to mice with 
advanced diabetic retinopathy in an attempt to rescue neurovascular dysfunction. (Figure 














Figure 1.3: A schematized view of the potential for Tie2 modulation in the diabetic 
retina. COMP-Ang1 would serve to promote endothelial survival, decrease 
leukocyte-endothelial interactions, and promote vascular barrier integrity by 
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a b s t r a c t
Simultaneous non-invasive visualization of blood vessels and nerves in patients can be obtained in the
eye. The retinal vasculature is a target of many retinopathies. Inﬂammation, readily manifest by leuko-
cyte adhesion to the endothelial lining, is a key pathophysiological mechanism of many retinopathies,
making it a valuable and ubiquitous target for disease research. Leukocyte ﬂuorography has been
extensively used in the past twenty years; however, ﬂuorescent markers, visualization techniques, and
recording methods have differed between studies. The lack of detailed protocol papers regarding
leukocyte ﬂuorography, coupled with lack of uniformity between studies, has led to a paucity of stan-
dards for leukocyte transit (velocity, adherence, extravasation) in the retina. Here, we give a detailed
description of a convenient method using acridine orange (AO) and a commercially available scanning
laser ophthalmoscope (SLO, HRA-OCT Spectralis) to view leukocyte behavior in the mouse retina. Normal
mice are compared to mice with acute and chronic inﬂammation. This method can be readily adopted in
many research labs.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
The eye uniquely lends itself to simultaneous non-invasive
visualization of blood vessels and nerves in patients. Many reti-
nopathies affect the retinal vasculature, in turn compromising
neural function. Inﬂammation is a key pathophysiological mecha-
nism of many retinopathies, making it a valuable and ubiquitous
target for disease research. Leukocyte adherence to the endothelial
lining of blood vessels is a key component of inﬂammation.
Leukocyte ﬂuorography has been extensively used in the past
twenty years (Janssen et al., 1994; Nishiwaki et al., 1995, 1996;
Iwama et al., 2008; Miyahara et al., 2004); however, ﬂuorescent
markers, visualization techniques, and recording methods have
differed between studies. To date there have been no detailed
protocol papers relating to leukocyte ﬂuorography in mice, result-
ing in a paucity of standards for leukocyte transit (velocity, adher-
ence, extravasation) in the retina. We describe a convenient
method using acridine orange (AO) and a commercially available
scanning laser ophthalmoscope (SLO, HRA-OCT Spectralis) to view
leukocyte behavior in the mouse retina and demonstrate that
leukocyte rolling and adhesion can be visualized in acute and
chronic inﬂammation.
Acridine orange (AO) is a cell permeable metachromatic ﬂuo-
rescent dye that has been widely used to assess apoptotic cells,
measure leukocyte adhesion, and quantify vascular ﬂow (as it binds
white but not red blood cells) (Janssen et al., 1994). After binding
double-stranded DNA, AO emits green ﬂuorescence with spectral
properties similar to sodium ﬂuorescein (peak excitation at 502 nm
and emission at 522 nm). Although a tried and tested technique,
in vivo AO leukocyte ﬂuorography (AOLF) has been predominantly
reserved for studies equippedwith a customized in-house scanning
laser ophthalmoscope on larger rodent models (Barouch et al.,
2000; Joussen et al., 2001). Even when AOLF was used with
commercially available SLOs, a video monitoring system developed
in-house developed was required for recording and analysis
(Miyamoto et al., 1998). While leukocyte ﬂuorography has been
tested in mice, it has either relied on alternative dyes which
required removal of leukocytes prior to staining and then re-
introducing the leukocytes back into the mouse (Xu et al., 2003),
or relied on in house video recording devices that required separate
set up (Iwama et al., 2008; Miyahara et al., 2004). This paper pre-
sents a method with simple administration of the ﬂuorescent agent
(tail vein injection of AO) and a commercially available imaging
system (Heidelberg Spectralis) which contains within its software
q Study supported by NEI RO1EY01796-01A1.
* Corresponding author. Tel.: þ1 801 213 2550.
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video recording capabilities. Standards for arteriole, capillary, and
venule leukocyte velocity are compared to previously reported data
as well as mouse models of acute (intravitreal injection of VEGF)
and chronic (diabetes > four months) inﬂammation.
2. Materials and supplies
2.1. Mice
All animals were treated in accordance with IACUC approval.
Three cohorts of mice obtained from Jackson laboratory were used
in this study. Male C57Bl6/J mice were compared to Ins2Akita
heterozygote male mice (diabetic, >600 mg/dL blood glucose), and
C57Bl6/J mice treated with intravitreal injections of VEGF (200 ng/
2 mL) to study chronic and acute inﬂammation, respectively. All
mice were aged 20e25 weeks. Mice injected intravitreally with
VEGF were observed the following day.
2.2. Scanning laser ophthalmoscope
Heidelberg Spectralis: HRA-OCT Spectralis (Heidelberg, Ger-
many) running software version 1.6.4.0 was used with a 488 nm
argon blue laser with a standard 500 nm long-pass ﬁlter.
2.3. Anesthetic
Isoﬂurane a mixture of 3% Isoﬂurane/O2 mixture in a closed
canister at a ﬂow rate of 1.0 Lpm. Anesthesia was maintained with
1.5% isoﬂurane/O2 mixture at same ﬂow rate.
2.4. Fluorescent agent
Acridine orange was purchased from Acros organics Acridine
orange (AO (Acros Organics, Geel, Belgium), 0.10%/PBS) and ﬁltered
with a 0.22 mm ﬁlter.
2.5. Video analysis
Video images acquired by Heidelberg Spectralis were trans-
ferred to .avi format using the included software. AVI ﬁles were
then opened in ImageJ using and analyzed with a plug in developed
by Peter Bankhead.
3. Detailed methods
3.1. Imaging mouse retina
Mice were anesthetized by an initial inhalation of 3% Isoﬂurane/
O2 mixture in a closed canister at a ﬂow rate of 1.0 Lpm. Anesthesia
was maintained with 1.5% isoﬂurane/O2 mixture at same ﬂow rate
and mice were placed on a heated water pad (37 !C). Pupils were
dilated with a 1% tropicamide solution and afterward hydrated
periodically with saline solution to prevent corneal desiccation.
Acridine orange (AO (Acros Organics, Geel, Belgium), 0.10%/PBS)was
ﬁlteredwith a 0.22 mm ﬁlter. The solution (0.05mL/min for a total of
1 min) was then injected into the tail vein of mice. Imaging was
accomplished using HRA-OCT Spectralis (Heidelberg, Germany)
with a 488 nm argon blue laser with a standard 500 nm long-pass
ﬁlter. Images were acquired from both eyes with a 55 ! lens while
restricting the visual ﬁeld to a 25 ! digital zoom to visualize an area
of 3.3 mm " 3.3 mm. Reducing the visual ﬁeld shortened the time
required to obtain horizontal scans therefore increasing the frame
rate. Utilizing the movie mode on the Heidelberg HRA OCT Spec-
tralis, videos were captured at 15.4 frames per second imaging in
High Speed mode. Endothelial staining of AO allowed for
identiﬁcation of larger retinal vessels in which leukocytes were
manually focused upon. To control forminor eyemovements, either
induced by the operator or themouse, video frameswere registered
after acquisition. Arteries and veinswere distinguishedby leukocyte
transit away from and toward the optic disc, respectively. Arteries
and veins, of which there were typically six each, were deﬁned as
emanating fromtheoptic nerve. Arteriolesweredeﬁnedas branches
coming from the central retinal arteries and leading to capillaries.
Capillaries connected the arterioles to the venules, which drained
back into the central retinal veins. Images focused on the superior
quadrant of the retina between artery, capillary bed, and vein. After
acquiring videos, animals were transferred to a recovery heat pad
and monitored until regaining full consciousness.
3.2. Analysis of videos
Videos were exported in .avi format from Heidelberg pro-
prietary software and opened in ImageJ software. Relevant leuko-
cytes were determined by those present in at least three frames in
the ﬁeld of view and 3 disc diameters away from the optic disc. At
least three leukocytes were tracked in each vessel type (3 per ar-
tery/iole, vein/ule, and capillary) in each eye and in each mouse
(n ¼ 18). Using a Cell Analyzer Plugin (developed by Peter Bank-
head) leukocytes were tracked in consecutive frames. Distances in
pixels were calculated and converted using Heidelberg’s automated
scaling metadata to microns (1.22 microns/pixel) after adjusting for
murine corneal radius of curvature of 1.4 mm. Multiplying distance
traveled between frames by 15.4 yielded individual velocities and
averages were calculated.
Leukocyte engagement and subsequent rolling along the
endotheliumwas also recorded and tracked using the Cell Analyzer
Plugin. Rolling leukocytes exhibited much slower transit times and
followed the vessel wall. Leukocytes were determined to be rolling
if they maintained contact with the vessel wall and could be
tracked for greater than 5 consecutive frames (with many
exceeding 10 frames).
3.3. In vitro leukocyte rolling
To determine whether acridine orange affected leukocyte-
endothelial interaction dynamics we tested human leukocyte roll-
ing over human retinal microvascular endothelial cells (HrMVEC,
human primary cells from Cell Systems, Kirkland, WA) in vitro (a
system wherein leukocytes are visible without acridine orange la-
beling). HrMVECswere cultured inparallel-plateﬁbronectin-coated
ﬂow chambers (Ibidi u-slide VI 0.4) until 80% conﬂuent and then
exposed to TNF-a (10 ng/mL) or vehicle control for three hours to
elicit an inﬂammatory and pro-adhesive response to leukocytes.
Leukocytes, obtained from venous whole blood of healthy human
donors, were isolated as described previously (Zhu et al., 2012),
diluted inwarmed ultrasaline (Lonza) to 1"10^6/ml and exposed to
acridine orange (0.15%) or vehicle control. Leukocyte solution was
then pumped through the parallel plate ﬂow chambers using a sy-
ringe pump (HarvardApparatus) at 1 dyn/cm^2 (typical venous shear
stress). Leukocyte adhesion and rolling was monitored using dif-
ferential interference contrast microscopy (DIC). DIC images were
acquired at a rate of 1/second for 1 min and the number of leuko-
cytes adhered or rolling on the endothelial monolayer was quanti-
ﬁed as leukocytes/frames/second. At least four independent ﬂow
wells were averaged to achieve the reported values (mean $ SD).
3.4. Results
In C57Bl6/J mice, leukocyte velocity was greatest in the arteries
and veins (18.07 $ 3 mm/s and 17.7 $ 2 mm/s, respectively).
J.M. Cahoon et al. / Experimental Eye Research 120 (2014) 15e1916
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Velocity decreased in arterioles and venules (6.9 ! 1 mm/s and
8.5 ! 1.1 mm/s, respectively) and was slowest in the capillaries
(1.7 ! 0.3 mm/s). These values were signiﬁcantly decreased in the
Ins2Akitamice and themice injectedwith VEGF (Table 1, Fig.1). The
number of rolling leukocytes in the venules and veins of normal
C57Bl6/J mice averaged 0.3 ! 0.8 within the ﬁeld of view (FOV)
(3 mm " 3 mm) over a ﬁve minute observation period, compared
with 13.5 ! 5.1 in the diabetic Ins2Akita mice and 8 ! 1.4 in the
VEGF-injected mice (Fig. 2). Data are shown in Table 1
(mean ! standard deviation, n ¼ 18 C57Bl6/J mice, 9 Ins2Akita
mice, 7 VEGF-injected C57Bl6/J mice).
3.5. Evaluation of extravasated leukocytes
To determine whether leukocytes had left the vasculature and
crossed into the retina, static images of the retina were taken
30 min after injection of acridine orange. By this time, leukocytes
were not visible traveling in the blood vessels (due to the washout
effect (Iwama et al., 2008), and leukocytes appeared outside major
vessels). The number of leukocytes counted in the still image was
taken to represent the number of leukocytes that left the vascula-
ture and extravasated into the retina. 1.48 ! 1.04 leukocytes
migrated out of the vasculature and into the FOV in normal C57Bl6/J
mice, as analyzed thirty minutes after AO injection. VEGF injection
dramatically increased leukocyte extravasation (13 ! 6.3 leuko-
cytes). Ins2Akita mice also demonstrated increased leukocyte
extravasation (7.1 ! 3.3 leukocytes). Leukocyte extravasation was
conﬁrmed using confocal microscopy to visualize leukocytes
(CD11b, BD Biosciences, San Jose, California) and vessels (isolectin
GS-IB4, Life Technologies, Carlsbad, California) on retinal ﬂatmount
(Fig. 3). It should be noted that confocal microscopic imaging
revealed more extravasated leukocytes than could be observed
with the ophthalmoscope.
3.6. In vitro leukocyte rolling
While TNF-a increased leukocyte adhesion and rolling in vitro,
acridine orange had no effect on leukocyte adhesion or rolling in
either the inﬂammatory (TNF-aþ) (36 ! 5, without acridine orange
vs. 31 ! 6, with acridine orange leukocyte frames/sec) or non-
inﬂammatory (TNF-a%) (4 ! 1, without acridine orange vs. 3 ! 1,
with acridine orange leukocyte frames/sec) conditions (n ¼ 4 wells
per condition; p ¼ 0.68 between AO þ and AO %)(Fig. 4). Acridine
orange did not affect leukocyte adhesion to the endothelium in the
presence or absence of TNF-alpha.
4. Potential pitfalls and troubleshooting
4.1. Eye opacity
Visualization became limited after cataracts began to form due
to continued anesthesia. This limited visualization for each mouse
to a temporal window of 5 min. Several methods were employed to
reduce cataract formation: 1) mice were placed on a heated water
pad during imaging, 2) moisture of mouse eyes was maintained
with periodic drops of phosphate buffered saline and wicked away
with a cotton tip applicator to allow for clear visualization, 3) im-
aging time was limited to 5 min maximum. By following these
practices, clarity persisted allowing for useful imaging.
4.2. Continuous tail vein injections
Tomaintain a continuous ﬂow of acridine orange into themouse
we employed use of a butterﬂy catheter needle (25 gauge) attached
Table 1
Leukocyte velocity in C57Bl6/J mice is given in each area of the vascular tree. Leukocyte transit times of diabetic Ins2Akita mice and C57Bl6/J treated with intravitreal injections
of VEGF are given as well. Diabetic mice had slower leukocyte velocities in the arterioles, capillaries, venules, and veins (p < 0.0001), while VEGF-injected mice experienced
slower transit times in the capillaries, only (p < 0.001).
Velocity (mm/sec)
Artery Arteriole Capillary Venule Vein
Mouse type C57BI6/J 18.1 ! 3 6.9 ! 1 1.7 ! 0.4 8.5 ! 1 17.7 ! 2
Ins2Akita 12.8 ! 1 3.7 ! 0.8* 0.7 ! 0.2* 2.7 ! 0.5* 3.6 ! 0.4*
C57BI6/J þ VEGF 12.5 ! 1.1 7.2 ! 0.8 0.7 ! 0.1* 6.4 ! 1 13.7 ! 1
* ¼ p < 0.001.
Fig. 1. Graph demonstrating leukocyte velocity in each segment of the vascular tree.
Leukocyte velocity was slower in diabetic Ins2Akita mice compared to normal mice in
all areas except the central retinal arteries. VEGF injection decreased leukocyte transit
time in the capillaries.
Fig. 2. The number of rolling leukocytes counted over a ﬁve minute observation period
following acridine orange administration. Leukocyte rolling was increased in diabetic
Ins2Akita mice and mice injected with VEGF.
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to a 1 mL syringe. After the needle was placed into the tail vein
(conﬁrmed with low resistance when pressure was applied to the
plunger) the needle was taped in place allowing for a small bolus to
be applied every 30 s. If too many leukocytes were observed in the
FOV, making counting and tracking difﬁcult, AO solution could be
injected intraperitoneally to dilute the concentration and allow for
a slower absorption into the circulation.
4.3. Speed of recording
To increase the frame rate High Speed mode was selected and
FOV was narrowed to a 3 mm ! 3 mm area of the retina; this
allowed us to record at 15.4 frames/sec.
5. Discussion
Herewepresent a detailed descriptionof the establishedmethod
of following leukocytes in vivo. Leukocytes can be easily visualized
and tracked after tail vein injectionof acridineorange inmice usinga
commercially available system (HRA-OCT Spectralis), mitigating the
need for custom-built in house video monitoring systems making
this technique feasible for many laboratories that already routinely
image the mouse retina. By deﬁning the normal parameters of
leukocyte behavior in vivo in the mouse retina, this technique es-
tablishes baseline characteristics against which leukocyte behavior
in inﬂammatory stress models or therapeutic models can be
compared. Previously reported data for average leukocyte velocity
in arterioles, venues, and capillaries comes from a study by Xu et al.,
in Balb/Cmice and B10. RIII mice using C-AM labeled leukocytes (Xu
et al., 2002). However, results reported here, though slightly slower,
are still in alignment with these results despite a different back-
ground of mouse and leukocyte ﬂuorescent agent.
There are some limitations to our study that merit future
mechanistic investigation and technical enhancements. Higher
magniﬁcation and resolution would enable assessment of ﬁrmly
adherent cells. It is possible that some of the “extravasated leuko-
cytes” are en face capillaries, but this is unlikely as we observed
carefully for ﬂow within these structures by using different angles
of visualization. Extravasated cells retain acridine orange longer
than endothelial cells mainly due to the washout effect (Xu et al.,
Fig. 3. Leukocyte extravasation was seen 30 min after acridine orange administration with the scanning laser ophthalmoscope and was conﬁrmed with confocal microscopy.
Fig. 4. To determine whether acridine orange altered leukocyte endothelial in-
teractions, human leukocytes were rolled across a human retinal microvascular
endothelial cell monolayer at a constant rate. Leukocytes could be visualized under
microscope and adhering leukocytes were counted in each frame. Results are shown as
leukocyte frames/minute for each condition. While TNF-a increased leukocyte adhe-
sion, acridine orange did not alter leukocyte adhesion in either the presence or absence
of TNF-a.
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2003). Extravasated cells may be a speciﬁc subset of leukocytes and
not representative of leukocytes in general. Elucidating this and
characterizing the surface markers of extravasated leukocytes
would require separating retinal interstitial tissue from retinal
vessels, or performing acridine orange leukography in the relatively
avascular retina of rabbits. Most importantly, assessing the impact
of retinal vascular hyperpermeability on extravasation in models of
retinal disease that disrupt the blood-retinal barrier would have the
most translational value.
Future studies with this approach could explore in vivo studies
of leukocyte dynamics in diabetic retinopathy, retinal vein occlu-
sion, uveitis, or other inﬂammatory conditions. If dynamic leuko-
cyte behavior was signiﬁcantly different in these conditions, it
would be easy to envision developing a system where imaging
these parameters in patients (with a non-toxic leukocyte ﬂuo-
rophore as opposed to acridine orange) could be of diagnostic,
prognostic, or disease monitoring value. Tagging leukocytes and
endothelial or neural cells with different ﬂuorophores would
enable high-resolution imaging of leukocyte interactions with
other retinal components with an appropriate multi-spectal im-
aging system. Further, labeling of leukocytes with long-wavelength
ﬂuorophores would theoretically facilitate imaging of leukocyte
dynamics in the pigmented choroid. In conclusion, leukocytes can
be easily visualized and tracked after tail vein injection of acridine
orange in mice using a commercially available system (HRA-OCT
Spectralis), bypassing the need for complex in house video moni-
toring, making this technique feasible for many laboratories that
already routinely image the mouse retina.
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3.1 Abstract 
Diabetic retinopathy is the leading cause of blindness in the working-age 
population in the US. Hyperglycemia induces neuroglial dysfunction in the retina, which 
occurs in unison with vascular cell damage leading to breakdown of the blood retinal 
barrier, vasodegeneration, and ischemia. Currently, no therapies exist for normalizing the 
vasculature in diabetic retinopathy. Here, we show that a single intravitreal dose of 
adeno-associated virus serotype 2 encoding a stable, soluble form of Ang1 
(AAV2.COMP-Ang1) ameliorated structural and functional hallmarks of diabetic 
retinopathy with sustained effects observed through six months. AAV2.COMP-Ang1 
single-dose gene therapy modulated the expression of vascular markers, such as VE-
cadherin and VEGF-A, which were expressed in levels comparable to nondiabetic 
controls, and preserved retinal vascular integrity in the diabetic mouse. Furthermore, 
AAV2.COMP-Ang1 prevented retinal thinning and ganglion cell layer dropout and 
largely preserved visual tracking and electroretinographic response. In mice with 
established diabetic retinopathy, COMP-Ang1 enhanced the therapeutic benefit of 
intravitreally-delivered endothelial colony-forming cells by promoting integration into 
the vasculature, which significantly stemmed further visual decline. AAV2.COMP-Ang1 
can prevent neural and vascular pathology in early diabetic retinopathy and promote 





Diabetes affects 25.8 million people in the United States and its prevalence is 
expected to triple in the next 20 years (Wong et al., 2009; Yau et al., 2012). Diabetic 
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retinopathy (DR) is the leading cause of blindness in the working-age population (Wild, 
Roglic, Green, Sicree, & King, 2004). The leading cause of vision loss in DR is diabetic 
macular edema (DME), largely induced by vascular hyperpermeability associated with 
breakdown of the blood retinal barrier (BRB) (Murata et al., 1995). DME is currently 
treated by laser photocoagulation and monthly intravitreal injections of agents that block 
vascular endothelial growth factor (VEGF). These treatments fail to improve vision in a 
significant number of patients (Brown et al., 2013), and have risks of retinal burns, 
detachment, hemorrhage, infection, or pain (Jager, Aiello, Patel, & Cunningham, 2004). 
Current treatment of DME only slows, but does not stop, progression (Campochiaro, 
Wykoff, Shapiro, Rubio, & Ehrlich, 2014). Moreover, since VEGF is neurotrophic, its 
blockade in the long-term has been associated with retinal toxicity in rodents and 
potentially in patients (Quaggin, 2012). This project advances a new approach that works 
by reversing retinal vascular damage and restoring normal perfusion to improve vision in 
diabetic retinopathy. 
The underlying pathogenesis of DR is largely due to hyperglycemia (Dornan, 
Mann, & Turner, 1982). Hyperglycemia increases inflammatory responses leading to 
leukocyte adhesion, microvascular occlusion, and consequent hypoxia (Adamis et al., 
2001a; Joussen et al., 2004). Further, hyperglycemia induces pericyte loss, compromising 
endothelial stability and blood retinal barrier (BRB) integrity. Eventual capillary 
degeneration leads to retinal nonperfusion, exacerbating retinal hypoxia (Mizutani, Kern, 
& Lorenzi, 1996). Consequent pathological VEGF-induced angiogenesis is 
uncoordinated and results in immature, leaky vessels with inadequate perfusion, creating 
a vicious cycle of hypoxia-driven VEGF secretion (Aiello et al., 1994; Hammes et al., 
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2004). Retinal ganglion cell loss, neuronal dysfunction, and changes in vision are also 
seen in patients with DR and this occurs in unison with vascular pathology (Byeon, Chu, 
Lee, Lee, & Kwon, 2009; Gastinger, Singh, & Barber, 2006; van Dijk et al., 2009). As a 
therapeutic goal, vascular stabilization could promote normal perfusion of the 
metabolically demanding retinal neuropile and prevent sight-threatening sequelae of 
ischemia.   
Patients with DR have decreased vitreous Angiopoietin 1 (Ang1) (J. I. Patel, 
Hykin, Gregor, Boulton, & Cree, 2005). Ang1, via the Tie2 endothelial receptor, induces 
vessel quiescence and maturation, and decreases vascular leakage by preventing VEGF-
induced degradation of vascular endothelial (VE)-cadherin, a transmembrane protein in 
the adherens junction between endothelial cells that promotes vascular integrity and 
decreases vascular permeability (Aldrich et al., 1996; Gavard, Patel, & Gutkind, 2008; 
Thurston et al., 2000). Further, Ang1 promotes survival of damaged vascular endothelial 
cells through PI3K/Akt signaling (Augustin, Young Koh, Thurston, & Alitalo, 2009). 
Thus, restoration of Ang1 signaling could serve as a potential treatment to prevent 
endothelial loss, retinal ischemia, and abnormal VEGF expression in DR (Joussen et al., 
2002). Pharmaceutical development of Ang1 as a viable therapy has been hindered by its 
insolubility and aggregation. Ten years ago, a novel, stable, soluble and more potent 
version of Ang1, cartilage oligo matrix protein Ang1 (COMP-Ang1), was developed to 
overcome the limitations of native Ang1 (Cho et al., 2004). 
Acellular capillaries, a hallmark of diabetic retinopathy, lead to nonperfusion, and 
could theoretically be recellularized and refunctionalized by endothelial progenitor cells 
(EPCs) (Medina, O'Neill, Sweeney, Guduric-Fuchs, Gardiner, Simpson, et al., 2010b). 
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However, CD34+ EPCs isolated from diabetic patients have a decreased ability to 
associate with the existing vascular networks (“Circulating mononuclear progenitor cells: 
differential roles for subpopulations in repair of retinal vascular injury,” 2013). The term 
EPC encapsulates a diverse group of cell-types with myeloid, haematopoietic or 
endothelial characteristics (Stitt et al., 2011) and this explains the conflicting clinical trial 
outcomes using these cells in cardiovascular disease (O'Neill et al., 2012).  A unique EPC 
subtype, known as endothelial colony-forming cells (ECFCs, also known as outgrowth 
endothelial cells (OECs)), has been shown to encompass true endothelial progenitors 
which fully integrate into blood vessels and serve to regenerate damaged vasculature in 
the ischemic retina (Medina, O'Neill, Humphreys, Gardiner, & Stitt, 2010a), as well as 
other ischemic models (Alphonse et al., 2014).  These cells have yet to be investigated as 
possible reparative cells in the context of the damaged diabetic retinal vasculature.  
To model DR, we used the type 1 diabetic Ins2Akita mouse, which harbors a 
mutation in the insulin gene that prevents proper insulin secretion, inducing 
hyperglycemia (Barber et al., 2005; Gastinger et al., 2006; Huang et al., 2011). 
Progressive retinal abnormalities begin 12 weeks after the onset of hyperglycemia and 
include apoptosis (demonstrated by endothelial and ganglion cell loss) and functional 
deficits (increased vascular permeability and decreased neuronal function) (Akimov & 
Rentería, 2012). 
We hypothesized that constitutive expression of COMP-Ang1 could prevent 
vascular endothelial destabilization in a model of early diabetic retinopathy and restore 
lost vasculature when administered in combination with ECFCs. Here, we show that 
constitutive expression of COMP-Ang1 via the adeno-associated virus serotype 2 
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(AAV2) viral vector, a safe and effective vector for retinal disease (Maguire et al., 2008), 
delivered before the onset of the retinopathy in Ins2Akita mice prevents vascular 
structural and functional breakdown, accompanied by preservation of neurovascular 
structure and function. Additionally, we found that COMP-Ang1 increases ECFC 
tubulogenesis and migration in vitro. Finally, we demonstrate COMP-Ang1 can increase 




3.3 Material and methods 
C57BL/6-Ins2Akita/J (Ins2Akita) and its background strain, C57BL6/J, mice were 
obtained from The Jackson Laboratory (Sacramento, USA) and bred in our pathogen-free 
animal facility. Mice heterozygous for the Ins2 mutation experience hypoinsulinemia and 
hyperglycemia by four weeks of age. This research protocol was approved by the 
Institutional Animal Care and Use Committee of the University of Utah and conforms to 
the standards in the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
research. Blood sugar level was measured by using OneTouch® Ultra®2 (LIFESCAN 
Johnson & Johnson Company, Milpitas, CA, USA). We used only male Ins2Akita with 
blood sugar levels greater than 600 mg/dL or age-matched controls. 
Plasmids, pAAV2.COMP-Ang1 and pAAV2.AcGFP, were made. Cassettes from 
these were integrated into viral vectors driven by the CMV promoter, to generate 
AAV2.COMP-Ang1 and AAV2.AcGFP. By integrating cDNA of COMP-Ang1 to 
pAAV-MCS (Agilent Technologies, Santa Clara, USA), pAAV2.COMP-Ang1 was 
generated. As a control, pAAV2.AcGFP was also generated using AcGFP cDNA from 
pIRES2-AcGFP1 (Clontech Laboratories, Mountain View, USA). Each serotype 2 AAV 
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vector was generated in the Vector Core Gene Therapy Center, University of 
Massachusetts Medical School.    
Each mouse was anesthetized with 0.025 mL Avertin (1.25% 
tribromoethanol)/gram of body weight intraperitoneally. At two months of age, mice 
were randomly assigned to receive 2.0 x 109 AAV2 particles or the same volume of PBS 
(2 µl) injected into the vitreous cavity of both eyes with a 33-gauge micro syringe 
(Hamilton Company, Reno, USA). 
Primer sequences for PCR are: COMP-Ang1 F 5`-
GCTCTGTTTTCCTGCTGTCC-3` COMP-Ang1 R 5`-GTGATGGAATGTGACGCTTG 
-3` and, as an internal control, glyceraldehyde 3-phosphate dehydrogenase (GAPDH): 
GAPDH F 5`-AACTTTGGGATTGTGGAAGGG -3` GAPDH R 5`-
ACCAGTGGATGCAGGGATGAT -3`. 
At six months of age the retina was harvested and placed in 200 µl of RIPA buffer 
(Sigma-Aldrich, St. Louis, USA) containing a protease and phosphatase inhibitor cocktail 
(Roche Diagnostics Corporation, Indianapolis, USA). Samples were subjected to 
immunoprecipitation using ANTI-FLAG M2 Affinity Gel (Sigma-Aldrich) following the 
manufacturer’s instructions. We detected COMP-Ang1 protein using ANTI-FLAG M2 
antibody (Sigma-Aldrich). For detection of other proteins, we used anti-VEGF-A (1:200, 
Santa Cruz Biotechnology, Inc, Santa Cruz, USA), anti-VE cadherin (1:1000, Abcam, 
Cambridge, USA), anti-GAPDH (1:3000, Abcam) and anti-phospho-Src (PY419, 1 
µg/mL, R&D) and anti-β-actin (1:3000, Abcam) as a primary antibody.  
Eyes were fixed with 4% paraformaldehyde for two hours at 4º C, and incubated 
in sucrose overnight. After embedding in optimal cutting temperature compound (Sakura, 
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Torrance, USA) globes were cut in 10µm sections. Sections were stained with anti-VE 
cadherin antibody (1:200, Abcam, Cambridge, USA) for 40 minutes at 37ºC, washed 
with PBS and stained with AlexaFluor 546 conjugated secondary antibody for 30 minutes 
at 37º C. Following DAPI staining sections were mounted with anti-fading reagents. 
Eyes were placed in 4% paraformaldehyde/PBS at 4ºC for two hours. 
Preparations were stained with 1:200 α-SMA antibody conjugated with Cy3 (Sigma-
Aldrich, St. Louis, USA) and 5µg/ml Alexa 647 conjugated isolectin GS-IB4 (Invitrogen 
Corporation, Carlsbad, USA) in blocking buffer overnight at 4º C. After washing, the 
retina was flatmounted on a glass slide. Fluorescence images were captured with 
scanning laser confocal microscopy (Olympus America Inc. Center Valley, USA).  
Measurements of transendothelial electrical resistance were performed with the 
electrical cell–substrate impedance sensing (ECIS) system (Applied Biophysics, Troy, 
USA). HrMVECs were seeded (50,000 cells/well) onto fibronectin-coated gold 
microelectrodes in ECIS culture wells (8W10E+) and incubated overnight at 37°C in 
EBM-2 media supplemented with EGM2-MV until cell resistance reached a plateau. 
Cells were serum starved for one hour until resistance was stabilized (1200 Ω). 
Treatments were added to each well, and monitoring was continued for 21 hours. The 
data from triplicate wells were averaged and presented as normalized resistance versus 
time. 
Evans Blue (EB) (Sigma-Aldrich) assay was used to assess retinal permeability. 
Animals were administered Evans Blue (20mg/kg) through tail vein injection. After four 
hours, animals were sacrificed and retinae were harvested in formamide at 70ºC for 18 
hours. Samples were centrifuged for two hours at 40,000 g in a 0.2µm filter and EB 
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concentration was detected spectrophotometrically by subtracting absorbance at 620 nm 
from 740 nm. Green fluorescent protein (GFP) conjugated microspheres (100 nm in 
diameter) were injected into the tail vein of mice (100 µL/20 gram mouse). Mouse eyes 
were imaged immediately after injection, as well as 30 minutes after injection to observe 
any residual extravasation. Because we were unable to distinguish GFP microspheres in 
mice treated with AAV2.GFP, we utilized the ICG modality on Heidelberg Spectralis to 
visualize 100 nanometer microspheres (Magsphere) conjugated with the near infrared 
fluorophore ZW800 (Flare Foundation).  
Leukocyte-endothelial interaction dynamics were tested using human leukocytes 
rolled over human retinal microvascular endothelial cells (HrMVEC) in vitro. HrMVECs 
were cultured in parallel-plate fibronectin-coated flow chambers (Ibidi u-slide VI 0.4) 
until 80% confluent and then exposed to TNF-α (10ng/mL) or vehicle control for three 
hours to elicit an inflammatory and pro-adhesive response to leukocytes. Leukocytes 
were isolated as described previously in accordance with IRB protocol (Zhu et al., 2012), 
diluted in warmed ultrasaline (Lonza) to 1 x 106/ml. Leukocyte solution was then pumped 
through the parallel plate flow chambers using a syringe pump (Harvard Apparatus) at 1 
dynes/cm2 (typical venous shear stress). Differential interference contrast (DIC) images 
were acquired at a rate of 1/second for one minute and the number of leukocytes adhered 
or rolling on the endothelial monolayer was quantified as leukocytes/frames/second. At 
least three independent flow wells were averaged to achieve the reported values (mean 
+/- stdev). 
Mice were anesthetized by an initial inhalation of 3% Isoflurane/O2 mixture in a 
closed canister at a flow rate of 1.0 Lpm. Pupils were dilated with a 1% tropicamide 
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solution and afterwards hydrated periodically with saline solution to prevent corneal 
desiccation. Acridine orange (AO (Acros Organics, Geel, Belgium), 0.10%/PBS) was 
filtered with a 0.22 µm filter. The solution (0.05mL/min for a total of one minute) was 
then injected into the tail vein of mice. Imaging was accomplished using HRA-OCT 
Spectralis (Heidelberg, Germany) with a 488nm argon blue laser with a standard 500nm 
long-pass filter. Images were acquired from both eyes with a 55 degree utilizing the 
movie mode on the Heidelberg HRA OCT Spectralis.  
Each mouse was anesthetized as described above and pupils were dilated with a 
drop of 1% tropicamide. Using Spectralis® HRA+OCT (Heidelberg Engineering GmbH, 
Heidelberg, Germany), fluorescence images were captured to determine AcGFP 
expression in the retina. Retinal thickness of each mouse was determined in vivo using 
optical coherence tomography (OCT). Retinal thickness was measured 250µm relative to 
the optic nerve head determined by measurements from the OCT-derived en face image. 
Retinal thickness was measured in the four retinal quadrants and averaged to produce a 
single value for each retina. 
Optomotor reﬂex-based spatial frequency threshold tests were conducted in a 
visuomotor behavior measuring system (OptoMotry; CerebralMechanics, Lethbridge, 
AB, Canada). Tracking was deﬁned as a reproducible smooth pursuit with a velocity and 
direction concordant with the stimulus. Trials of each direction and spatial frequency 
were repeated until the presence or absence of the tracking response could be established 
unequivocally. Spatial frequency of the stimulus was stepped up or down with the 
staircase method to find the behavioral threshold, corresponding to the visual acuity for 
the behavior. Rotation speed (12°/s) and contrast (100%) were kept constant.  
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Electroretinography (ERG) was performed on dark adapted mice anesthetized in 
dim red light with ketamine/xylazine (10 mg/kg) and placed on a controlled warming 
plate (TC-1000, CWE Instruments, Ardmore, PA) that maintained temperature. ERGs 
were measured (UTAS E-3000; LKC Technologies, Gaithersburg, MD) between a gold 
corneal and a stainless-steel scalp electrode with a 0.3 to 500-Hz band-pass ﬁlter. 
Scotopic ERGs were recorded with ﬂash intensities increasing from -3.62 to -1.61 log(cd 
s/m2). The photoﬂash unit was calibrated by LKC Technologies to deliver 2.5 cd s/m2 at 
0 dB ﬂash intensity. 
Fresh human cord blood was obtained under full ethical approval at the Northern 
Ireland Blood Transfusion Service from healthy volunteers (Belfast, United Kingdom). 
Mononuclear cells (MNCs) were obtained by density gradient fractionation. To obtain 
ECFCs, MNCs were resuspended in complete medium (EGM-2 MV; Lonza Ltd.) 
supplemented with 10% FBS and seeded on 24-well culture plates precoated with rat tail 
collagen type 1 (BD Biosciences, Bedford, UK) at a density of 1 x 107 cells/mL. Three 
different clones of ECFCs were used for each experiment. For in vivo testing, one clone 
type was chosen and used in all mice. Cells were labeled with QTracker from Invitrogen 
according to manufacturer’s instructions (Qdot 655) before being delivered via 
intravitreal injection. At six months, mice were treated with intravitreal injection of 
AAV2.COMP-Ang1, AAV2.AcGFP, or PBS. Two weeks after delivery of the virus mice 
were then injected with the 1x105 ECFCs (labeled with QTracker 655, Invitrogen).   
All data are presented as mean ± stdev. For statistical analysis between two 
samples we used a two-tailed Student’s t-test, α level 0.05. ANOVA was used for 
comparison between four groups, p<0.05 was considered significant, followed by Tukey 
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To achieve constitutive expression of COMP-Ang1 in the mouse retina, we 
delivered AAV2 encoding COMP-Ang1 (AAV2.COMP-Ang1) through intravitreous 
injections. AAV2 has been safe and effective in clinical trials with intravitreal use 
(Simonelli et al., 2010). As revealed by in vivo confocal fluorescence imaging and ex vivo 
evaluation of retinal flat mounts, Aequorea coerulescens green fluorescent protein 
(AcGFP) fluorescence was observed following AAV2.AcGFP particle injection. 
Fluorescence was initially observed one-week postinjection and persisted through six 
months, the endpoint of our first cohort of mice. AcGFP fluoresced in all retinal 
quadrants at the level of the ganglion cell layer, as previously reported (Yin et al., 2011). 
COMP-Ang1 mRNA and protein expression was confirmed by reverse transcriptase 
polymerase chain reaction (RT-PCR) and immunoblotting from the mouse retina, 
respectively.   
Two of the principal features of diabetic retinopathy are pericyte and capillary 
dropout with consequent vascular hyperpermeability and ischemia (Cogan, Toussaint, & 
Kuwabara, 1961). We observed that a single injection of AAV2.COMP-Ang1 delivered 
intravitreally at age two months prevented the retinal vessel loss observed in Ins2Akita 
mice at age six months (Figure 3.1a). Endothelial staining decreased in the PBS and 
AAV2.AcGFP treated Ins2Akita mice compared to WT, (P<0.001) (Figure 3.1b). 
AAV2.COMP-Ang1 restored retinal endothelial coverage to (p=0.02 vs. AAV2.AcGFP).  
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Figure 3.1: COMP-Ang1 mitigates diabetic retinal capillary dropout. (a) Representative 
retinal flatmounts prepared from six month-old mice and stained for isolectin (endothelial 
cell marker, green) and α-SMA (smooth muscle marker, red). Ins2Akita mice 
experienced pericyte and endothelial dropout; the latter was prevented with a single 
intravitreous dose of AAV2.COMP-Ang1. Scale bars  = 600 µm (top). Trypsin digest 
featuring of retinas representative of each group. Black arrow heads denote acellular 
capillaries (bottom).  (b) Quantification using ImageJ of endothelial coverage and (c) 
pericyte coverage. (d) Acellular capillaries were manually counted and averaged over an 
area 1mm2.  Eight eyes were used in each analysis, data are mean ± stdev. *p<0.001, 
ANOVA. Post hoc comparisons with a Tukey test to compare means of each group. Scale 
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Pericyte coverage in diabetic Ins2Akita mice decreased compared to controls and 
was not rescued by AAV2.COMP-Ang1 (Figure 3.1c). These data suggest that 
AAV2.COMP-Ang1 provides Ang1 endothelial-trophic signaling in lieu of pericytes, 
which are known to be the major source of endogenous Ang1 in the capillary unit 
(Aldrich et al., 1996). Trypsin digest preparations confirmed that acellular capillaries 
were reduced in diabetic mice with COMP-Ang1 treatment compared to control treated 
diabetics (Figure 3.1a,c) (p<0.05).   
To assess whether the improved vascular morphology was accompanied by 
improved function, we determined whether COMP-Ang1 enhanced barrier function in 
human retinal microvascular endothelial cells (HrMVECs) and the mouse retina. COMP-
Ang1 increased, and VEGF decreased, the transepithelial resistance of HrMVECs, as 
measured by electric cell-substrate impedance sensing (ECIS) (Figure 3.2a) (Tiruppathi, 
Malik, Del Vecchio, Keese, & Giaever, 1992). While retinal vascular permeability was 
not marked on fluorescein angiography (McLenachan, Chen, McMenamin, & Rakoczy, 
2013), breakdown of the BRB was quantified using Evans Blue permeability into the 
retina (Adamis, Xu, & Qaum, 2001b) and this was elevated in control-treated Ins2Akita 
diabetic mice relative to wildtype (WT) mice. Intravitreal AAV2.COMP-Ang1-treatment 
in Ins2Akita diabetic mice restored Evan’s blue permeability to baseline levels 
comparable to that observed in the WT retina (Figure 3.2b). These findings were further 
supported by two separate qualitative assessments of vascular permeability in vivo. 
Fluorescent microspheres (100 nm in diameter; labeled with GFP or ZW800 (an NIR 
fluorophore), whose emission wavelengths are detectable by the Heidelberg Spectralis 
confocal scanning laser ophthalmoscope in the FA or ICG modes, respectively, were  
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 Figure 3.2: COMP-Ang1 enhances barrier function and reduces ischemia. (a) Graph of 
ECIS of HrMVECs with COMP-Ang1, VEGF, or PBS added to the media. COMP-Ang1 
increased resistance of HrMVECs (n=3). (b) Evans Blue extravasation from the retina of 
Ins2Akita mice was increased compared to control; treatment with AAV2.COMP-Ang1 
returned vascular hyperpermeabilty to control levels. *P<0.001 compared to C57BL/6-J, 
**P=0.02 compared to AAV2.AcGFP. (c) GFP or the NIR fluorophore ZW800 were 
conjugated to aminated latex microspheres (GFP-ms, or ZW800–ms; 100 nm in diameter) 
and injected into the tail vein of three mice per group. Leakage was captured using the 
FA or ICG imaging modality on Spectralis, respectively. (d) Increased VE-cadherin and 
decreased phosphorylated Src expression in HrMVEC treated with COMP-Ang1 
compared to controls (n=3). (e) Ins2Akita mouse retinas have increased VE-cadherin and 
decreased VEGF-A concentrations in mice treated with AAV2.COMP-Ang1. (f) COMP-
Ang1 reduced TNF-α induced leukocyte rolling in cultured HrMVECs. (g) COMP-Ang1 
prevents leukostasis and inflammation (h) Representative retinas (four mice per group) 
from mice treated with hypoxyprobe (pimonidazole). COMP-Ang1 reduced hypoxia in 
diabetic mouse retinas. Scale bars: 600 µm (h) *P<0.001, ANOVA. Post hoc 
comparisons with a Tukey test to compare means of each group. 
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observed. Microsphere leakage was increased in the diabetic mice and prevented by 
COMP-Ang1 administration (Figure 3.2c). This indicates that retinal vascular leakage 
can be suppressed despite persistent pericyte dropout.   
To clarify the molecular underpinnings of COMP-Ang1-mediated enhancement of 
BRB integrity, we determined its influence on Src phosphorylation and VE-cadherin 
expression in human retinal microvascular endothelial cells (HrMVECs). VEGF-A 
induces vascular leakage through Src-mediated downregulation of VE-cadherin, while 
Ang1 promotes VE-cadherin expression (GAVARD et al., 2008; Thurston, 2002). As 
expected, COMP-Ang1 decreased Src phosphorylation and increased VE-cadherin in 
HrMVECs (Figure 3.2d). These findings were consistent with retinal levels of VE-
cadherin in Ins2Akita mice (Figure 3.2e). Interestingly, COMP-Ang1 treatment also 
reduced VEGF-A levels in the retina of Ins2Akita mice (Figure 3.2e).  Collectively and 
consistent with prior reports on Ang1 activity, these mechanistic data indicate that 
COMP-Ang1 likely reduces vascular endothelial permeability through decreased Src 
phosphorylation and increased VE-cadherin. Decreases in VEGF-A retinal protein could 
be mediated by a decrease in retinal hypoxia, as shown by pimonidazole staining (Figure 
3.2h). COMP-Ang1-mediated perfusion enhancement was associated with reduced retinal 
VEGF-A expression, contributing further to vascular stability.  
The Ins2Akita mouse, like patients with DR, experiences inflammatory responses 
to diabetes (Huang et al., 2011). Leukocyte adhesion to the vascular wall is mediated, in 
part, by TNF-α (Vinores, Xiao, Shen, & Campochiaro, 2007). We determined that 
COMP-Ang1 decreased TNF-α induced leukocyte adherence to an endothelial monolayer 
in vitro (Figure 3.2f). Furthermore, acridine orange leukocyte fluorography (Cahoon et 
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al., 2014) indicated that COMP-Ang1 reduces leukocyte adherence in the capillaries of 
the mouse retina (Figure 3.2g).  Increased leukocyte rolling in the diabetic retina was 
suppressed with AAV2.COMP-Ang1 treatment.  
Consistent with previous reports (Joussen et al., 2002), our data support that 
constitutive delivery of Ang1 can suppress the vascular dysfunction in diabetic mice. 
However, whether this therapy improves retinal neuronal health has yet to be elucidated.  
To determine whether promoting a more robust vascular network in diabetic mice 
correlated with improved retinal structure, we assessed the effects of COMP-Ang1 on 
retinal ganglion cell layer loss (van Dijk et al., 2009) by examining retinal cross-sections 
(ex vivo) and retinal thickness (in vivo using optical coherence tomography (OCT)) 
between AAV2.COMP-Ang1 injected Ins2Akita mice and control mice (Figure 3.3a). 
Retinal thickness of Ins2Akita mice treated with either PBS or AAV2.AcGFP declined 
compared to C57BL/6JL6 mice (P<0.0001), but was preserved by AAV2.COMP-Ang1 
treatment (P=0.006 vs. AAV2.AcGFP) (Figure 3.3b). This was followed up with ex vivo 
cross sections of retina labeled for nuclei staining (Figure 3.3c). Ganglion cell layer 
nuclei were counted in each group. AAV2.COMP-Ang1 treatment prevented loss of 
ganglion cell layer nuclei in Ins2Akita mice (Figure 3.3d), suggesting that this therapy 
may be beneficial in preventing diabetes-induced retinal ganglion cell death. Further, we 
saw no evidence of toxicity or cell loss in the rest of the retina due to AAV2.COMP-
Ang1. 
Finally, we assessed whether AAV2.COMP-Ang1 could preserve retinal 
physiological function in addition to inducing structural and vascular improvements. We 
tested whether AAV2.COMP-Ang1 could rescue visual tracking behavior and retinal  
   55 
 
 
Figure 3.3: COMP-Ang1 prevents diabetes-induced retinal ganglion cell layer 
degeneration and stabilizes visual function. (a) Representative figures from optical 
coherence tomography (OCT) measuring retinal thickness. The red line indicates the 
retinal surface and Bruch’s membrane. Scale bars  = 200 µm. (b) Cross sections of six 
month-old retina from WT, or Ins2Akita mice treated with PBS, AAV2.AcGFP, or 
AAV2.COMP-Ang1 stained with DAPI. (c) View of the ganglion cell layer from mice 
stained for VE-cadherin (red) or nuclei (DAPI, blue) demonstrating increased VE-
cadherin and nuclear staining. Scale bars 30 µm (right). (d) Quantification of retinal 
thickness from OCT showing that AAV2.COMP-Ang1 prevented diabetes-induced 
retinal thinning as measured in vivo (*p<0.0001 vs. WT, P=0.006 vs. AAV2.AcGFP). 
AAV2.COMP-Ang1 prevented diabetes-induced inner retinal layer loss (*p=0.03 
ANOVA, with post hoc Tukey test). (e) Representative example of ERG response from 
all groups of mice. Electrical retinal response was elicited and the amplitude of b-wave 
during scotopic conditions at -3.62 log (Cd s/m2), -2.62 log (Cd s/m2), -1.62 log (Cd 
s/m2), intensity was recorded. Decreased amplitudes were recorded in Ins2Akita mice 
treated with PBS or AAV2.AcGFP compared to WT mice and AAV2.COMP-Ang1 
prevented the decrease in amplitude. *p=0.0001, ANOVA. Assessing visual acuity was 
accomplished by testing optomotor tracking response of Ins2Akita mice treated with 
AAV2.COMP-Ang1 or control compared to WT. (f) Ins2Akita mice exhibited decreased 
optokinetic tracking response (units = cycles/degree). AAV2.COMP-Ang1 prevented the 
decrease in visual response; six mice from each group were tested, data are mean ± stdev. 
*P<0.001, ANOVA. 
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electrical responses, which are impaired in diabetic retinopathy (Bresnick, Korth, Groo, 
& Palta, 1984). AAV2.COMP-Ang1 treatment, compared to AAV2.AcGFP or PBS, 
prevented the diabetes-induced reduction in electroretinographic (ERG) scotopic b-wave 
amplitudes in Ins2Akita mice (Figure 3.3e), which would be impaired due to anomalous 
photoreceptor-bipolar communication (Hombrebueno, Chen, Penalva, & Xu, 2014). 
Furthermore, AAV2.COMP-Ang1 treatment prevented the diabetes-induced reduction in 
visual tracking response as measured by using the optomotor head tracking response task 
to determine spatial visual thresholds (Barabas et al., 2011) (Figure 3.3f). These spatial 
resolution and electroretinographic findings demonstrate that AAV2.COMP-Ang1 can 
preserve retinal function in the face of prolonged diabetes. 
Thus far, our data demonstrate a protective role for COMP-Ang1 when delivered 
early (age two months) to the diabetic mouse retina. In ischemic retina, successful 
regeneration has been shown using intravitreal delivery of ECFCs in the oxygen-induced 
retinopathy model (Medina, O'Neill, Humphreys, Gardiner, & Stitt, 2010a) but their 
potential has not yet been explored in the diabetic retina. Ang1 promotes differentiation 
of embryonic or induced pluripotent stem cells into vasculogenic cells, which undergo 
vascular engraftment and facilitate vessel regeneration. Hence, there is clear potential for 
COMP-Ang1 to mobilize or enhance the normal function of these endogenous, reparative 
cells. 
To serve as an effective treatment clinically, we tested the ability of COMP-Ang1 
to enhance ECFC function in vitro and promote their integration into the diabetic retinal 
vasculature in vivo. We sought to determine whether COMP-Ang1 would improve the 
functional benefit of treatment with ECFCs, which express high levels of the 
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Angiopoietin-1 receptor, Tie2 (Medina, O'Neill, Sweeney, Guduric-Fuchs, Gardiner, 
Simpson, et al., 2010b). 
We demonstrated that COMP-Ang1 increases migration and tubulogenesis of 
ECFCs in vitro, as assessed by scratch migration assay and matrigel tube formation 
assay, respectively (Figure 3.4a,b). To explore the potential of in vivo retinal vascular 
repair, diabetic mice at six months of age were given intravitreal injections of 
AAV2.COMP-Ang1 or controls (AAV2.AcGFP or PBS). Two weeks later, labeled 
ECFCs (Qdot-655, Invitrogen) were administered intravitreally. In one cohort of mice, 
retinas were harvested 72 hours after injection of ECFCs, stained for endothelial cells, 
and mounted flat for confocal analysis. COMP-Ang1 enhanced ECFC integration into the 
diabetic retina (Figure 3.4c). Three-dimensional reconstruction of confocal 
immunofluorescence images demonstrates enhanced ECFC engraftment onto retinal 
vessels in diabetic mice treated with AAV2.COMP-Ang1 relative to control. A second 
cohort of mice was followed for two months to determine whether this combination 
therapy achieved significant visual outcomes. The optokinetic tracking response was 
stabilized in mice treated with COMP-Ang1 and ECFCs, yet declined in control mice, 




We demonstrated the salutary effects of COMP-Ang1 in ameliorating these 
pivotal pathogenic events in diabetes and hallmarks of diabetic macular edema and 
ischemia. AAV2.COMP-Ang1 reduced VEGF-A and increased VE-cadherin expression 
in Ins2Akita mice, consistent with a model of vascular normalization. Strikingly, 
structural and functional indices of endothelial homeostasis were restored by 
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Figure 3.4: COMP-Ang1 enhances ECFC engraftment into the diabetic retina and 
prevents further visual decline. (a) Endothelial colony-forming cells (ECFCs) were plated 
on collagen-coated wells and assayed for migration potential under increasing doses of 
COMP-Ang1. (b) Additionally, 3D tube formation was tested in matrigel. COMP-Ang1 
increased migration and tube formation in a dose dependent manner with maximal effects 
exerted at 500 ng/mL. (c) ECFCs were injected in aged diabetic mice (six months, arrow) 
after the mice had been treated with COMP-Ang1 or control. ECFCs were labeled with 
qdots (655) and injected intravitreally. Three days later retinas were harvested and 
stained for blood vessels (isolectin 546) and flatmounted for confocal analysis. COMP-
Ang1 increased ECFC integration into the diabetic retinal vasculature (see also 
Supplemental Video). (d) Mice treated with COMP-Ang1 or control plus ECFCs were 
analyzed for visual tracking ability. COMP-Ang1 plus ECFCs prevented further declines 
in spatial frequency threshold.  *p<0.05, in vitro experiments were performed in triplicate 
on three different ECFC clones (total of nine experiments per condition). In vivo 
experiments were performed on five mice per group (ten eyes). Scale bars: 600 µm (top), 
150 µm (middle), and 90 µm (bottom). *P<0.001, ANOVA. Post hoc comparisons with a 
Tukey test to compare means of each group. 
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AAV2.COMP-Ang1 despite concomitant pericyte loss in the capillaries, which is often 
present prior to onset of therapy in diabetics. This indicates a potential role for 
AAV2.COMP-Ang1 in arresting vascular dysfunction and disruption. Furthermore, 
AAV2.COMP-Ang1 preserved the retinal ganglion cell layer, the loss of which is an 
integral cause of decreased vision in diabetic retinopathy.  
 Based on our data, our working model is that AAV2.COMP-Ang1 normalizes the 
vasculature by decreasing Src phosphorylation and increasing and VE-cadherin stability, 
enhancing vascular integrity and preventing the endothelial cell loss seen in Ins2Akita 
mice. These processes result in normalized vasculature, enhanced perfusion, reduced 
hypoxia-driven VEGF production (further contributing to vascular stability) and reduced 
ganglion cell layer loss. The decrease in VEGF production could derive from either 
COMP-Ang1 mediated decrease in retinal hypoxia or via inhibition of macrophage-
produced VEGF (J. Lee et al., 2013).  Recently, Ang-1 has demonstrated neuroprotective 
effects in the CNS (Shin et al., 2010). In this study, AAV2.COMP-Ang1 restored visual 
acuity and ERG responsiveness, which often decrease in diabetic patients.  
Most intriguingly, from a perspective of reparative therapy for advanced diabetic 
retinopathy, we found that COMP-Ang1 increases ECFC vasculogenic capabilities and 
promotes their integration into and engraftment with the diabetic retinal vessels. This was 
functionally relevant as the combination of AAV2.COMP-Ang1 and ECFCs stemmed 
further visual decline in mice with advanced diabetes, as determined by visual tracking 
response.   
This work compliments the recent findings of those published by Lee et. al (J. Lee 
et al., 2013) that angiopoietin-1 can help recover from oxygen-induced retinopathy and 
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laser-induced CNV. Our manuscript advances the field by 1) showing that sustainable 
delivery can be achieved with a single intravitreal injection, 2) testing the effects of 
COMP-Ang1 in a model of diabetic retinopathy, and most importantly 3) showing that 
COMP-Ang1 can enhance the regenerative capacity of endothelial progenitor cells in a 
retina with advanced diabetes.  
 Engineered COMP-Ang1 avoids the issues of aggregation and insolubility, and 
we have shown here that COMP-Ang1 gene therapy can replace deficient Ang1 secretion 
by pericytes, which are lost in diabetic retinopathy. In conclusion, we suppressed retinal 
vascular leakage, preserved retinal morphology, and prevented diabetes-induced deficits 
in visual acuity and retinal function in the diabetic Ins2Akita mouse retina with a single 
intravitreous injection, which afforded long-term expression of COMP-Ang1 delivered 
by AAV2. Furthermore, COMP-Ang1 enhanced ECFC integration into the retina of mice 
with advanced diabetes, stemming further visual decline. This therapy suppresses the 
pathognomonic features of nonproliferative diabetic retinopathy and, in contrast to 
existing therapies, decreases the nonperfusion and ischemia critical to the genesis of 
proliferative diabetic retinopathy. Our data indicate that COMP-Ang1 has significant 
potential to prevent retinal vascular endothelial cell damage during diabetes. Moreover, 
enhanced expression of this vasotrophic growth factor enhances the established 
vasoregenerative properties of ECFCs delivered to the diabetic retina as cell therapy. 
COMP-Ang1 could prove useful for vascular normalization in diabetic retinopathy and 
other conditions, which entail vascular ischemia. Further studies will focus on type 2 
diabetes and larger animal models of diabetic retinopathy.  
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ABSTRACT The KDR gene, which participates in
angiogenesis and lymphangiogenesis, produces two
functionally distinct protein products, membrane-
bound KDR (mbKDR) and its isoform, soluble KDR
(sKDR). Since sKDR does not have a tyrosine kinase
domain and does not dimerize, it is principally an
antagonist of lymphangiogenesis by sequestering
VEGF-C. Alternative polyadenylation of exon 30 or
intron 13 leads to the production of mbKDR or sKDR,
respectively, yet the regulatory mechanisms are un-
known. Here we show that an antisense morpholino
oligomer directed against the exon 13-intron 13 junc-
tion increases sKDR (suppressing lymphangiogenesis)
and decreases mbKDR (inhibiting hemangiogenesis).
The latent polyadenylation site in intron 13 of KDR is
activated by blocking the upstream 5= splicing site with
an antisense morpholino oligomer. Intravitreal mor-
pholino injection suppressed laser choroidal neovascu-
larization while increasing sKDR. In the mouse cornea,
subconjunctival injection of the morpholino-inhibited
corneal angiogenesis and lymphangiogenesis, and sup-
pressed graft rejection after transplantation. Thus, this
morpholino can be used for concurrent suppression of
hemangiogenesis and lymphangiogenesis. This study
offers new insight into the mechanisms and potential
therapeutic modulation of alternative polyadenyla-
tion.—Uehara, H., Cho, YK., Simonis, J., Cahoon, J.,
Archer, B., Luo, L., Das, S. K., Singh, N., Ambati, J.,
Ambati, B. K. Dual suppression of hemangiogenesis
and lymphangiogenesis by splice-shifting morpholinos
targeting vascular endothelial growth factor receptor 2
(KDR). FASEB J. 27, 76–85 (2013). www.fasebj.org
Key Words: alternative polyadenylation ! corneal graft
rejection
Blood vessel network formation (vasculogenesis
and angiogenesis) are necessary for maintenance of the
body in vertebrates (1). Many diseases (e.g., cancer,
rheumatoid arthritis, macular degeneration, diabetic
retinopathy) are due to uncontrolled neovasculariza-
tion (2–6). Vascular endothelial cell growth factor A
(VEGF-A) and KDR [also referred to as vascular endo-
thelial growth factor receptor 2 (VEGFR2)] play central
roles in physiological and pathological angiogenesis (7,
8). The KDR gene produces 2 functionally distinct
protein products, membrane-bound KDR (mbKDR)
and its isoform soluble KDR (sKDR) by alternative
polyadenylation (9, 10). The mbKDR has an extracel-
lular domain consisting of 7 immunoglobulin domains,
a transmembrane domain, and tyrosine kinase domains
(7, 8) and is the primary angiogenic receptor for
VEGF-A. While mbKDR is composed of 30 exons in
humans and mice, sKDR is produced by utilization of
polyadenylation signals within intron 13 in mice. Since
sKDR does not have tyrosine kinase domains and has
much more affinity for VEGF-C than VEGF-A, it is an
antagonist of VEGF-C, the key driver of lymphangio-
genesis (9, 10). Thus, the membrane-bound isoform of
KDR is prohemangiogenic, while the soluble isoform of
KDR is antilymphangiogenic.
1 Correspondence: Moran Eye Center, University of Utah,
65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA.
E-mail: bala.ambati@utah.edu
doi: 10.1096/fj.12-213835
This article includes supplemental data. Please visit http://
www.fasebj.org to obtain this information.
Abbreviations: cDNA, complementary DNA; CNV, choroi-
dal neovascularization; DPBS, Dulbecco’s phosphate-buffered
saline; EST, expressed sequence tag; HUVEC, human umbil-
ical vein endothelial cell; KDR_MOe13, morpholino oli-
gomer targeting exon 13-intron 13 junction in human KDR;
mbKDR, membrane-bound KDR; moKDR_MOe13, morpho-
lino oligomer targeting exon 13-intron 13 junction in mouse
KDR; RACE, rapid amplification of cDNA ends; sKDR, soluble
KDR; STD_MO, standard morpholino; TFMS, trifluorometh-
anesulfonic acid; UTR, untranslated region; VEGF-A, vascular
endothelial cell growth factor A; VEGFR2, vascular endothe-
lial growth factor receptor 2 (also referred to as KDR)
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Here we report that a morpholino antisense oli-
gomer can shift splicing of KDR pre-mRNA from the
membrane to the soluble isoform in human umbilical
vein endothelial cells (HUVECs). The induced sKDR
requires utilization of a polyadenylation signal in intron
13, which is usually not activated in HUVECs. In
addition, morpholino intravitreal injection suppressed
laser choroidal neovascularization while increasing vit-
reous sKDR. Furthermore, in a mouse corneal suturing
model, injection of the morpholino into the subcon-
junctival space suppressed corneal angiogenesis and
lymphangiogenesis, and suppressed graft rejection in
mouse corneal transplantation. Our results indicate
that exon recognition by splicing factors affects subse-
quent polyadenylation signal activation and that by
modifying it, latent polyadenylation signals can be
activated, inducing alternative isoforms of proteins. We
believe that this study elucidates alternative polyadenyl-
ation and that modification of this mechanism could
potentially be a new drug target.
MATERIALS AND METHODS
Morpholino oligomer and primer sequences
Morpholino oligomers were purchased from Gene Tools
(Philomath, OR, USA). Sequences of the morpholino oligom-
ers and primers are listed in Table 1.
Cell cultures, morpholino delivery, and total RNA
extraction
HUVECs (Lonza, Walkersville, MD, USA) were cultured in
endothelial basal medium (EBM) with endothelial growth
medium SingleQuot Kit supplements and growth factors
(Lonza) according to the manufacturer’s instructions. To
prevent loss of endothelial cell properties, cell cultures were
limited to passages 4 to 7. As a mouse endothelial cell, MS-1
(American Type Culture Collection, Manassas, VA, USA)
were cultured in 5% FBS/DMEM. Morpholinos were deliv-
ered by nucleofection (Amaxa, Gaithersburg, MD, USA)
using Basic Nucleofector Kit for Primary Mammalian En-
dothelial Cells (Amaxa) program A-034 for HUVECs and
MS-1 cells. For one nucleofection, 1 ! 106 cells were used
and plated on a 6-well plate. Total RNA was extracted using
the RNeasy mini kit (Qiagen, Valencia, CA, USA) with
DNaseI treatment.
Complementary DNA (cDNA) synthesis and real-time PCR
cDNAs were synthesized from 400 ng total RNA using the
Omniscript RT kit (Qiagen) and Oligo-dT primer (dT20)
according to the manufacturer’s instructions. Real-time PCR
was performed using the QuantiTect SYBR Green PCR Kit
(Qiagen) and 1 "l of cDNA. Real-time PCR conditions: 95°C
for 10 min, followed by 40 cycles of 94°C for 15 s, 55°C for 30
s, and 72°C for 30 s.
3= rapid amplification of cDNA ends (RACE)
cDNA was synthesized using cloning_R1. PCR was performed
using the LongRange PCR Kit (Qiagen). PCR conditions were
93°C for 3 min, 35 cycles of 93°C for 15 s, 55°C for 30 s, and
68°C for 6 min using KDR_F and cloning_R2. Specific bands
were subjected to DNA sequencing. To determine endoge-
nous 3= untranslated region (UTR) of sKDR mRNA, total
RNA extracted from one human cornea was obtained from
the Utah Lions Eye Bank (Salt Lake City, UT, USA). cDNA
was synthesized with the same above method, and PCR was
performed using cloning_F(1042-1061), which is designed in
human KDR intron 13, and cloning_R2.
TABLE 1. Morpholino oligomer and primer sequences























Upper and lower case in morpholino oligomer sequences correspond to exon and intron,
respectively. Morpholino oligomer sequences were synthesized.
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Flow cytometry
At 3 d after nucleofection, cells were treated with trypsin-
EDTA and incubated in mouse anti-KDR antibody (ab9530,
1:1000; Abcam, Cambridge, MA, USA) with 10% FBS and 1%
sodium azide/PBS for 60 min. After 3 washes, the cells were
incubated in Alexa Fluor 647 conjugated anti-mouse IgG
(Invitrogen, Carlsbad, CA, USA) for 30 min. The cells were
washed 3 times, and fluorescence was detected by a FACScan
Analyzer (BD Biosciences, San Jose, CA).
Western blot for sKDR and mbKDR from HUVECs
After nucleofection, cells were cultured in a 75-cm2 flask for 3 d
without changing the medium. The medium was collected, and
cell debris was removed by centrifugation. Trichloroacetic acid
(Fisher Scientific, Pittsburgh, PA, USA) was added to the super-
natant; final concentration of trichloroacetic acid was 10%. After
incubation for 30 min on ice, they were centrifuged at 12 000 g
4°C for 5 min. Supernatants were discarded, and cold acetone
was added to the pellet. Centrifugation was repeated, the
acetone was discarded, and 800 !l of RIPA buffer was added.
Samples were sonicated and subjected to SDS-PAGE under
reducing conditions. The same primary antibody in flow cytom-
etry was used for immunobloting.
Deglycosylation of sKDR
Culture medium (2 ml) from HUVECs treated with morpho-
lino oligomer targeting exon 13-intron 13 junction in human
KDR (KDR_MOe13; 2 d culture) was freeze dried. Each
sample was treated by 200 !l cold Dulbecco’s phosphate-
buffered saline (DPBS) or trifluoromethanesulfonic acid
(TFMS) for 10 and 20 min. After adding 1 ml of cold 1 M
Tris-Cl buffer (pH 8.8), the proteins were condensed with
trichloroacetic acid precipitation. The pellet was dissolved
with 100 !l of RIPA buffer. The same antibody for sKDR
detection in Western blot was used.
Intravitreous injection of morpholino and Western blot for
sKDR and mbKDR from mouse eye
On d 0 and 3, 2 !l of 100 ng/!l morpholino oligomer targeting
exon 13-intron 13 junction in mouse KDR (moKDR_MOe13),
standard morpholino (STD_MO), or DPBS was injected
intravitreously. On d 4, retinal total RNA was extracted with
the RNeasy mini kit with DNaseI treatment for real-time
RT-PCR. For Western blot of mbKDR, on d 4, retina was
dissolved in RIPA buffer. For Western blot of sKDR, on d 4,
intraocular solution was obtained from 6 eyes by pipette.
After centrifugation, supernatant was used for further exper-
iments. For detection, biotin-conjugated anti-KDR (BAF644;
R&D Systems, Minneapolis, MN, USA) was used at 1 !g/!l.
Laser-induced choroidal neovascularization (CNV)
Laser photocoagulation and CNV measurement were described
previously (11). Briefly, laser photocoagulation (532 nm, 150 mV,
100 ms, 100 !m) was performed on both eyes (2–5 spots/eye).
Laser CNVs were stained with 5 !g/ml Alexa488 -onjugated isolec-
tinGS-IB4 (Invitrogen), and observed by laser confocalmicroscope
(Olympus America, Center Valley, CA,USA). Supplemental Fig. S1
summarizes the condition of intravitreous injection in each exper-
iment. After photocoagulation, on d 1 and 4, 2 !l of 100 ng/!l
STD_MO or moKDR_MOe13, 500 ng/!l goat IgG (AB-108-C;
R&D Systems), 500 ng/!l goat anti-mouse VEGF-A IgG (AF-493-
NA; R&D Systems), or 2 ng/!l SU1498 (572888; EMD Chemicals,
Gibbstown, NJ, USA) was injected intravitreously.
TUNEL assay
TUNEL assay was performed using Click-iT TUNEL Alexa
Fluor 594 Imaging Assay (C10246; Invitrogen). DPBS,
STD_MO, or moKDR_MOe13 was injected into normal
mouse eyes or laser-photocoagulated eyes (1 d postlaser) as
described above. After 2 d, the eyes were fixed with 4%
paraformaldehyde for 2 h at 4°C, and incubated in 15%
sucrose for 2 h and 30% sucrose overnight. After embedding
in optimal cutting temperature (OCT) compound (Sakura
Finetek, Torrance, CA, USA), they were cut into 12-!m
sections. Staining for apoptosis was conducted with the man-
ufacturer‘s protocol. DNase-I treated section was used for
positive control.
Transmission electron microscopy
To examine the integrity of fenestration in choriocapillaris
after intravitreous moKDR_MOe13 injection, we examined
the choroid with a transmission electron microscope, follow-
ing previously described methods (12, 13).
Mouse corneal injury and observation of CD31 and LYVE-1
in cornea flat mount
Experimental conditions are listed in Supplemental Fig. S1.
Under anesthesia, 15 !l of moKDR_MOe13 (40 ng/!l),
STD_MO (40 ng/!l), or DPBS was injected subconjunctivally
into 2 different places. The corneas were fixed in acetone at
room temperature for 20 min. After 4 washes in PBST (0.1%
Tween20/PBS), the corneas were incubated in 3% BSA/PBS at
4°C for 3 d. Then corneas were incubated in 3%BSA/PBS with
FITC-conjugated rat anti-CD31 antibody (553372, 1:500; BD
Biosciences) and rabbit anti-LYVE-1 (ab14917, 1:200; Abcam)
overnight at 4°C. After 3 washes, the corneas were incubated in
3% BSA/PBS with Alexa Fluor 546-conjugated goat anti-rabbit
IgG (A11071, 1:2000; Invitrogen) for 1 h at room temperature.
After 4 washes, corneas were mounted on glass slides with
Fluoro-gel (Electron Microscopy Sciences, Hatfield, PA, USA).
Fluorescence was observed by fluorescence microscope (Carl
Zeiss MicroImaging, Thornwood, NY, USA). The data for each
suture were calculated separately by ImageJ (U.S. National
Institutes of Health, Bethesda, MD, USA).
Mouse corneal transplantation
Mouse corneal transplantation was described previously (9, 14).
The donor cornea was marked with 2 mm trephine, the anterior
chamber was penetrated using a knife (ClearCut; Alcon, Hünen-
berg, Switzerland), and the cornea was cut with Vannas scissors
and then placed in balanced salt solution. The recipient mouse
was anesthetized with ketamine (100 mg/kg body weight) and
xylazine (20 mg/kg body weight). To dilate the pupil and
anesthetize the cornea, 1% tropicamide ophthalmic solution
and 0.5% proparacaine ophthalmic solution were used. The
recipient’s right cornea was marked with 1.5 mm trephine and
removed by the same method as the donor cornea. Viscoelastic
material (Healon,1% sodium hyaluronate; Abbott Medical Op-
tics, North Chicago, IL, USA) was used during recipient cornea
dissection. The donor graft was sutured into the recipient bed
using interrupted sutures (11-0 nylon, CS160-6; Ethicon, Somer-
ville, NJ, USA). After the transplantation, the eye was covered
with 0.5% erythromycin ophthalmic ointment, and the lid was
sutured with 8-0 coated vicryl (BV130-5; Ethicon). All sutures
78 Vol. 27 January 2013 UEHARA ET AL.The FASEB Journal ! www.fasebj.org  
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remained for the first postoperative week. We injected 15 !l
moKDR_MOe13 (40 ng/!l), STD_MO (40 ng/!l), or DPBS
subconjunctivally on the day of transplantation and postopera-
tive 1, 2, 3, and 4 wk (Supplemental Fig. S1). The corneal opacity
was examined weekly using an operating microscope by the end
point (8 wk). The opacity was graded (from 0 to 5) to determine
graft rejection (15). Opacity of grade 3 or more was considered
to be graft rejection. At 8 wk, corneas were harvested and
subjected for CD31 and LYVE1 stain using the method de-
scribed above.
RESULTS
Blocking exon 13-intron 13 junction in KDR leads to
increased sKDR and decreased mbKDR at the mRNA
level
At first, we examined whether modulation of splicing
can lead to sKDR up-regulation and mbKDR down-
regulation. To modulate splicing, we used antisense
morpholino oligomers that bind mRNA or pre-
mRNA with high specificity to inhibit translation and
affect alternative splicing (16, 17). Antisense mor-
pholino oligomers were designed corresponding to
the junction of exon 13-intron 13 (KDR_MOe13; Fig. 1A
and the sequences in Table 1). Although the human
sKDR mRNA structure was not well characterized, we
utilized the expressed sequence tag (EST) database
and found the sequence of the initial 365 nt of intron
13, which include a stop codon at 48–50 nt. In
addition, 2 polyadenylation sites (AAUAAA) are
found in intron 13 (Fig. 1A). To introduce morpho-
lino into cultured cells, we performed nucleofection.
Fluorescent conjugated morpholino was used to con-
firm transfection into HUVECs (Fig. 1B). At 2 d after
morpholino transfection, sKDR and mbKDR mRNA
in HUVECs were examined by RT-PCR (Fig. 1C and
Figure 1. KDR_MOe13 decreases mbKDR mRNA and increases sKDR mRNA. A) Schematic design of KDR_MOe13. B)
Fluorescent morpholinos can be observed after nucleofection. Indicated amounts of each morpholino were nucleofected into
HUVECs. Scale bar " 100 !m. C) RT-PCR indicates mbKDR mRNA decrease and sKDR mRNA increase after KDR_MOe13. D,
E) Quantitative real-time PCR shows 40% decrease of mbKDR and 17-fold increase of sKDR mRNA. All results were normalized
by GAPDH and compared with DPBS-transfected HUVECs by 2-tailed Student‘s t test; n " 6/group. Bars represent means # se.
*P $ 0.05, ***P $ 0.001 vs. DPBS-transfected HUVECs.
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Supplemental Fig. S2). mbKDR mRNA decreased in
HUVECs transfected with KDR_MOe13 compared
with DPBS- or STD_MO-transfected HUVECs. On
the other hand, sKDR mRNA was increased by
KDR_MOe13. To quantify these results, real-time
PCR was performed (Fig. 1D, E). We found that
KDR_MOe13 down-regulates mbKDR mRNA by 40%
compared with STD_MO or DPBS (P!0.05). In con-
trast, sKDR mRNA showed a 17-fold increase
(P!0.001) with KDR_MOe13.
KDR_MOe13 increased sKDR and decreased mbKDR
protein
Next, we examined mbKDR protein expression by
Western blot. KDR_MOe13 reduced mbKDR protein
expression compared to DPBS and STD_MO (Fig. 2A).
On flow cytometry, in DPBS- and STD_MO-transfected
HUVECs, 83.3 and 81.0% were mbKDR positive, re-
spectively, while KDR_MOe13 decreased mbKDR posi-
tive cells to 40.7% (Fig. 2B). To confirm sKDR protein
expression, we performed Western blot from culture
medium of KDR_MOe13-transfected HUVECs using an
antibody recognizing KDR extracellular domains (Fig.
2C, D). Although the predicted molecular mass of
human sKDR is "76 kD, 150-kD bands were detected
from the culture medium of HUVECs transfected with
KDR_MOe13. Based on previous studies, mbKDR can
be glycosylated, increasing the molecular mass from
150 to 230 kD (18). In addition, sKDR has been
detected at 160 kDa, although it was not reported
whether this was derived from alternative polyadenyla-
tion or proteolytic cleavage from mbKDR (10). To
confirm glycosylation of sKDR, we attempted deglyco-
sylation of sKDR in medium from KDR_MOe13-treated
HUVECs using TFMS (Fig. 2E). We found that the
observed size of sKDR decreased from 150 to "70 kDa,
confirming glycosylation of sKDR.
Figure 2. KDR_MOe13 decreases mbKDR protein and increases sKDR protein. A) KDR_MOe13 decreased mbKDR protein
expression, as detected on Western blot. B) Flow cytometry demonstrates that KDR_MOe13 decreases mbKDR cell surface
expression. HUVECs stained with only secondary antibody were used as a negative control. C) Western blot from
concentrated culture medium shows that KDR_MOe13 induced sKDR (150-kDa band). D) sKDR protein detection from
conditioned culture medium without concentration. We exposed for a long period and enhanced the image. The 150-kDa
band (arrow) was detected from KDR_MOe13-transfected HUVEC culture medium strongly. E) Deglycosylation of sKDR
by TFMS. After deglycosylation, sKDR induced by KDR_MOe13 was observed at approximately calculated molecular weight
("70 kDa).
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Polyadenylation signal induced by KDR_MOe13 is the
same polyadenylation site as in endogenous sKDR
found in human cornea
Next, to determine the 3= UTR of sKDR mRNA
induced by morpholinos, 3= RACE was performed
(Fig. 3A). A strong band (!1600 bp) was detected
from KDR_MOe13-transfected HUVECs. Based on the
sequence of this band, sKDR mRNA utilizes a polyade-
nylation site located in the 1403- to 1408-nt range of
intron 13 (Fig. 3C). Based on this, we sought to identify
the 3= UTR of sKDR from human corneal total RNA
(Fig. 3B). Corneal tissue is known to predominantly
express sKDR (9). We found that in the human cornea,
sKDR mRNA utilizes the same polyadenylation site that
KDR_MOe13 induces (Fig. 3C).
KDR_MOe13 suppressed experimental
hemangiogenesis and lymphangiogenesis in vivo
Because KDR_MOe13 decreases mbKDR and increases
sKDR, we predicted that KDR_MOe13 can inhibit he-
mangiogenesis and lymphangiogenesis in vivo. There-
fore, we created moKDR_MOe13, which targets the
exon 13-intron 13 junction of mouse KDR. By RT-PCR,
we found that moKDR_MOe13 increased sKDR mRNA
and decreased mbKDR mRNA in mouse MS-1 cells
(Fig. 4A). To administer morpholinos in vivo, we devel-
oped morpholinos conjugated with dendrimer at the 3=
position (vivomorpholino; ref. 19). Vivomorpholino
possesses guanidinium head groups, which are pre-
dicted to help morpholino transport into cells through
binding with the phosphates of phospholipids. To
determine moKDR_MOe13 function in vivo, each mor-
pholino or DPBS was injected intravitreously, and the
retinal total RNA was subjected to real-time RT-PCR for
sKDR and mbKDR mRNA (Fig. 4B). moKDR_MOe13
significantly increased the sKDR/mbKDR mRNA ratio.
Next, we examined mbKDR and sKDR retinal and
vitreous protein by Western blot. Consistent with real-
time PCR results, moKDR_MOe13 decreased retinal
mbKDR protein (Fig. 4C) and increased vitreous sKDR
protein (Fig. 4D). Next, we examined whether moKDR_
MOe13 inhibits laser-induced CNV. Each morpholino
or DPBS was injected intravitreously on d 1 and 4 after
laser photocoagulation, and laser CNV volumes were
examined on d 7. Figure 4E shows representative
images of laser CNV with DPBS, STD_MO, and moKDR_
MOe13. moKDR_MOe13 significantly suppressed laser
CNV compared with STD_MO (P"0.05) and DPBS
(P"0.01) (Fig. 4F). In addition, moKDR_MOe13 treat-
ment was comparable to anti-VEGF-A IgG and KDR
kinase inhibitor (SU1498) treatment (Fig. 4G). We also
assessed apoptosis using TUNEL assay (Supplemental
Fig. S3). Mild apoptosis was observed after treatment
with moKDR_MOe13 and STD_MO. Furthermore, af-
ter morpholino intravitreous injection, fenestration in
Figure 3. Polyadenylation signal induced by KDR_MOe13 was the same polyadenylation signal
as in endogenous sKDR found in human cornea. A) 3= RACE was performed from total RNA
of DPBS-, STD_MO-, or KDR_MOe13-treated HUVECs. sKDR_F was used as a forward primer.
A !1600-bp band was observed on administering KDR_MOe13. B) 3= RACE was performed
from human corneal total RNA. Cloning_F(1042-1061) was used as a forward primer. C)
Sequence results of 3= RACE products from sKDR induced by KDR_MOe13 (sequence 1) and
sKDR of human cornea (sequence 2), along with genomic sequence of intron 13 in KDR gene
(sequence 3). Arrow indicates cleavage site.
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choriocapirallis was not affected by either moKDR_
MOe13 or control (Supplemental Fig. S4). For a sec-
ond model of angiogenesis, we used the corneal suture
model. For the 1-wk subarm, each morpholino or DPBS
was injected subconjunctivally 1 d before and 4 d after
suturing; the corneas were harvested 7 d postsuturing.
For the 2-wk subarm, each morpholino or DPBS was
injected subconjunctivally 1 d prior and 4, 7, and 10 d
after suturing; corneas were harvested at 14 d. CD31
and LYVE-1 were used as markers of neovascularization
and lymphangiogenesis, respectively. Figure 4H, I dis-
plays representative images of CD31-stained corneas at
1 wk and LYVE-1-stained corneas at 2 wk. Figure 4J, K
displays the mean area of neovascularization and lym-
phangiogenesis in each group. moKDR_MOe13 sup-
pressed suture-induced neovascularization by 52.2% (1
wk) and 29.6% (2 wk) compared to DPBS (P!0.001
and 0.05, respectively). moKDR_MOe13 did not sup-
press lymphangiogenesis 1 wk postsuturing but sup-
pressed lymphangiogenesis by 27.8% 2 wk postsuturing,
compared to DPBS (P!0.05).
KDR_MOe13 reduced graft rejection after mouse
corneal transplantation
Finally, we examined whether moKDR_MOe13 sup-
pressed murine corneal transplant rejection, which is
pathologically dependent on both hemangiogenesis
and lymphangiogenesis. After cornea transplantation,
moKDR_MOe13, STD_MO, or DPBS was injected sub-
conjunctivally. The corneas were observed with the
stereomicroscope (Fig. 5A).We found thatmoKDR_MOe13
increased graft survival compared with DPBS and
STD_MO (Fig. 5B, log rank test: P"0.0186 and 0.0610,
respectively). Figure 5C shows the representative im-
ages of CD31 and LYVE-1 stained cornea at the end
point (8 wk). Concordantly, moKDR_MOe13 signifi-
Figure 4. moVEGFR2_MOe13 suppresses experimental neovascularization and lymphangiogenesis in mice. A) RT-PCR from
MS-1 cells shows that moKDR_MOe13 decreases mbKDR mRNA and increases sKDR. B) Real-time PCR indicates that
intravitreous injection of moKDR_MOe13 increases sKDR/mbKDR mRNA ratio in mouse retina (n"4). C, D) moKDR_MOe13
decreased mbKDR protein and increased sKDR protein in vivo, as demonstrated by Western blots of mouse retina and vitreous.
E) Representative images of laser-induced CNV. F) moKDR_MOe13 suppressed laser-induced CNV relative to PBS or standard
nonspecific morpholino (n"11–17). G) moKDR_MOe13 suppressed laser-induced CNV volume by comparable amounts
relative to anti-mouse VEGF-A antibody and the KDR kinase inhibitor SU1498 (n"14–18). ANOVA: P " 0.000255. H, I)
Representative images of corneal neovascularization 1 wk after suture (H) and corneal lymphangiogenesis 2 wk after sutures (I).
J, K) moKDR_MOe13 suppressed neovascularization at 1 and 2 wk (J), and decreased lymphangiogenesis at 2 wk (K) compared
with the controls. Scale bars " 100 #m. P values were calculated by 2-tailed Student’s t test (n"13–16). Bars represent means $ se.
*P ! 0.05, **P ! 0.01, ***P ! 0.001.
82 Vol. 27 January 2013 UEHARA ET AL.The FASEB Journal ! www.fasebj.org
 
   75 
 
cantly reduced neovascularization and lymphangiogen-
esis (Fig. 5D, E).
DISCUSSION
Generally, alternative splicing produces a variety of
isoforms from a single gene and contributes diversity.
For example, the VEGF-A gene produces VEGF121,
VEGF165, VEGF189, and VEGF206 by alternative splic-
ing, and the products may contribute to forming the
gradient of VEGF-A (20–22). Compared with alterna-
tive splicing, alternative polyadenylation is not yet well
understood despite its importance. In humans and
mice, EST database analysis indicated that !60% of
mRNA may result from alternative polyadenylation
(23). We can divide alternative polyadenylation into 2
classes. In the first class, the 3= UTR has !2 polyade-
nylation sites. Depending on which polyadenylation site
is used, the length of 3= UTR changes. The difference
of 3= UTR length affects stability and localization of
mRNA (24–26). In the second class, the active polyad-
enylation site exists in a different exon or intron. The
example of this type of alternative polyadenylation is
the immunoglobulin system in B cells (27, 28). This
type of polyadenylation is believed to be associated with
an alternative splicing event (29). The KDR gene would
represent this type of alternative polyadenylation.
In this study, we demonstrate that the latent polyad-
enylation site in intron 13 of KDR can be activated by
blocking the upstream 5= splicing site (exon 13-intron
13 junction) using KDR_MOe13, which decreased
mbKDR and increased sKDR at mRNA and protein
levels. The polyadenylation site induced by
KDR_MOe13 is normally inactive in HUVECs, prefer-
entially excluding intron 13 during physiological splic-
ing. KDR_MOe13 likely competes with U1snRNPs at
the exon 13-intron 13 junction. U1snRNPs may inhibit
downstream polyadenylation and are among the key
components for the splicing event, although U1snRNP-
Figure 5. moKDR_MOe13 suppresses graft rejection in mouse corneal transplantation. A) Representative stereomicroscope
images 3 wk after corneal transplantation show that corneal transplants treated with moKDR_MOe13 were clear and had less
inflammation than the others. B) Cumulative graft survival rate. moKDR_MOe13 increased graft survival rate compared with
DPBS and STD_MO (log rank test: P"0.0186 and 0.0610, respectively). Arrow indicates censored data. C) Representative images
of corneal neovascularization and lymphangiogenesis in mouse corneal transplants at 8 wk. Scale bar " 1 mm. D, E)
moKDR_MOe13 suppressed neovascularization (D) and lymphangiogenesis (E) in mouse corneal transplants at 8 wk. P values
were calculated by 2-tailed Student‘s t test (n"11–17). Bars represent means # se. *P $ 0.05, **P $ 0.01).
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independent RNA splicing has been demonstrated
(30–32). It is probable that KDR_MOe13 activates the
latent polyadenylation signal by inhibiting U1snRNP
binding to the exon 13-intron 13 junction.
Interestingly, the polyadenylation site induced by
KDR_MOe13 is the same polyadenylation site as in
endogenous sKDR found in human cornea. The se-
quence around the polyadenylation site indicates that a
cleavage site (CA dinucleotides) and a GU-rich region
are located 26 and 71 nt downstream of AAUAAA,
respectively (Fig. 3C). These sequence components are
similar to typical polyadenylation signals (29, 33). With-
out any direct modification of the polyadenylation
mechanism, KDR_MOe13 activates the latent polyade-
nylation signal. Thus, mbKDR-preferred cells, such as
HUVECs, are still able to recognize the latent polyade-
nylation signal. This indicates that endogenous sKDR
may be produced by splicing factor control, rather than
polyadenylation mechanism modification. To under-
stand altenative polyadenylation events, splicing factors
should be focused rather than polyadenylation mecha-
nisms themselves.
sKDR protein induced by KDR_MOe13 was pro-
cessed (glycosylation) and exported to culture medium
in vitro. These results indicated that sKDR has similar
binding capacity of mbKDR to VEGF-C and inhibits it in
extracellularly. We have shown the effectiveness of
morpholinos in vivo by using moKDR_MOe13 to sup-
press corneal neovascularization and lymphangiogen-
esis in a suture injury model in mice. These results
suggested also that sKDR induced by KDR_MOe13 has
binding capacity to VEGF-C.
siRNA therapies to block angiogenesis are currently
under development. We propose the use of morpholinos
to shift the functionality of proangiogenic mbKDR to
antiangiogenic sKDR as an alternative avenue for devel-
oping antiangiogenic therapies. siRNAs can knock down
target mRNA but lacks the distinct advantage that mor-
pholinos have in being able to not only knock down an
undesirable protein, but also produce a desirable protein
at the same time. The dual effect of knocking down one
protein, while concurrently increasing the translation of
another, could offer therapeutic advantages in the ability
to more precisely regulate protein levels. In addition,
unlike siRNA, morpholinos are of neutral charge and
induce a lesser inflammatory response and less off target
binding.
We used a vivomorpholino in vivo study, although the
dendrimer that enables cell entry has been reported to
have mild toxicity (34), and we found some toxicity
(Supplemental Fig. S3). To advance this further toward
clinical translation, in future studies, we will test cell-
penetrating peptides such as polyarginine or choles-
terol conjugation (to avoid use of dendrimers). Future
investigations will also explore the distribution and
duration of morpholinos in vivo using novel but cur-
rently unavailable vivomorpholinos with fluorophores.
To target delivery of morpholinos, nanoparticles may
also be employed.
Another potential application for our morpholino-
targeting KDR would be the area of oncology. Solid
tumors rely on both hemangiogenesis and lymphangio-
genesis for growth and metastasis. The approach de-
scribed herein holds great potential for solid tumor
therapy as it simultaneously suppresses formation of
both blood and lymphatic vessels.
A recent report showed that polyadenylation activa-
tion could induce soluble isoforms of several receptor
tyrosine kinases, including KDR (35). We confirm the
concept of activating a latent polyadenylation signal
using morpholino oligomers and demonstrate in vivo
utility in suppressing hemangiogenesis and lymphan-
giogenesis with therapeutic effect in 3 models of blind-
ing disorders, including macular degeneration, corneal
injury, and corneal transplant rejection. This has appli-
cations not only for antiangiogenesis or eye disease by
targeting KDR but also in other conditions where
regulatory manipulation of splicing and polyadenyla-
tion could have therapeutic valence.
This work was supported by a Research to Prevent Blind-
ness Physician Scientist Award, a U.S. Department of Veterans
Affairs Merit Award, and U.S. National Eye Institute grant
R01EY017950.
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Morpholino-Mediated Increase in Soluble Flt-1
Expression Results in Decreased Ocular and Tumor
Neovascularization
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Abstract
Background: Angiogenesis is a key process in several ocular disorders and cancers. Soluble Flt-1 is an alternatively spliced
form of the Flt-1 gene that retains the ligand-binding domain, but lacks the membrane-spanning and intracellular kinase
domains of the full-length membrane bound Flt-1 (mbFlt-1) protein. Thus, sFlt-1 is an endogenous inhibitor of VEGF-A
mediated angiogenesis. Synthetic mopholino oligomers directed against splice site targets can modulate splice variant
expression. We hypothesize that morpholino-induced upregulation of sFlt-1 will suppress angiogenesis in clinically relevant
models of macular degeneration and breast cancer.
Methods and Findings: In vivo morpholino constructs were designed to target murine exon/intron 13 junction of the Flt-1
transcript denoted VEGFR1_MOe13; standard nonspecific morpholino was used as control. After nucleofection of
endothelial and breast adenocarcinoma cell lines, total RNA was extracted and real-time RT-PCR performed for sFlt-1 and
mbFlt-1. Intravitreal injections of VEGFR1_MOe13 or control were done in a model of laser-induced choroidal
neovascularization and intratumoral injections were performed in MBA-MD-231 xenografts in nude mice. VEGFR1_MOe13
elevated sFlt-1 mRNA expression and suppressed mbFlt-1 mRNA expression in vitro in multiple cellular backgrounds
(p,0.001). VEGFR1_MOe13 also elevated sFlt/mbFlt-1 ratio in vivo after laser choroidal injury 5.5 fold (p,0.001) and
suppressed laser-induced CNV by 50% (p= 0.0179). This latter effect was reversed by RNAi of sFlt-1, confirming specificity of
morpholino activity through up-regulation of sFlt-1. In the xenograft model, VEGFR1_MOe13 regressed tumor volume by
88.9%, increased sFlt-1 mRNA expression, and reduced vascular density by 50% relative to control morpholino treatment
(p,0.05).
Conclusions: Morpholino oligomers targeting the VEGFR1 mRNA exon/intron 13 junction promote production of soluble
FLT-1 over membrane bound FLT-1, resulting in suppression of lesional volume in laser induced CNV and breast
adenocarcinoma. Thus, morpholino manipulation of alternative splicing offers translational potential for therapy of
angiogenic disorders.
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Introduction
Angiogenesis, though a fundamental physiologic process, is a
key pathogenetic feature of numerous disease states. At present,
therapeutic strategies have limited potential largely due to the fact
that the underlying mechanisms of angiogenesis are incompletely
understood. Work to elucidate the full complement of mediators
and mechanisms important for angiogeneis, and further apply this
knowledge in such a way to alter disease progression continues to
be the foremost goal within the field.
Identification of VEGF as a critical mediator of vessel growth
has been an important step to understanding the human condition
in terms of the underlying molecular events. VEGF has been
shown to be necessary and sufficient for ocular neovascularization
[1–4]. In fact, transgenic mice which over-express human VEGF
show widespread ocular neovascularization [5–6]. Additionally,
pioneering work by Judah Folkman in the early 1970’s demons-
trated that solid tumor growth required VEGF expression [7].
However, it is not fully known what specific molecular media-
tors regulate VEGF expression. Soluble Flt-1, first described by
Kendall and Thomas in 1993, is an alternatively spliced form of
the Flt-1 gene, also referred to as VEGF-receptor 1 [8]. This
alternative splicing event occurs within intron 13 such that sFlt-1
contains the ligand-binding domain, but lacks the membrane-
spanning and intracellular kinase domains of the full-length mem-
brane bound Flt-1 (mbFlt-1) protein [9]. As suggested by its
structure, sFlt-1 is a potent endogenous inhibitor of VEGF A-
induced angiogenesis [9]. While the full complement of sFlt-1
expression and function has not been described, it has been shown
to be both necessary and sufficient for maintenance of the
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avascular cornea [10]. In addition, recent work has demonstrated
a role for modulation of sFlt-1 in the development and treatment
of a form of pathologic ocular neovascularization termed choroidal
neovasculization (CNV), via modulation of VEGF ([11–12],
unpublished data). Choroidal neovascularization is characterized
by choroidal capillary growth through Bruch’s membrane beneath
the retinal pigmented epithelial (RPE) cell layer. This vascular
pathology is most classically seen in exudative or ‘‘wet’’ age-related
macular degeneration, the leading cause of vision loss in the
western world [13–14]. Furthermore, sFLT-1 has also been shown
to reduce VEGF expression and tumor vascularity in breast
adenocarcinoma xenografts [15]. Thus, sFlt-1 represents a
potential therapeutic target to reduce aberrant blood vessel growth
over a spectrum of disease.
Current therapies targeting both CNV and tumor vasculature
are focused on inhibiting the new vessel growth, and include such
modalities as photocoagulation, photodynamic therapy, anti-
VEGF intraocular injections, as well as systemic administration
of anti-VEGF monoclonal antibody. These approaches have
shown promise; however, they induce retinal damage, require
repeated intraocular administration, or have recently been
contraindicated for use in the case of systemic anti-VEGF therapy
for breast adencarcinoma [4,13,16–17]. Additionally though
certainly progress has been made, incomplete efficacy and
recurrence is commonly seen with all modalities. Development
of novel therapeutic techniques to either augment or circumvent
our current treatments is necessary to improve both efficacy and
the risk profile.
In this work, we describe the use of morpholino oligomers
promoting the expression of soluble Flt-1 as a means to determine
its potential for therapeutic use in disorders characterized by
aberrant neovascularization. This technology has human prece-
dent in Duchene Muscular Dystrophy, where morpholino
technology targeting the dystrophin gene has shown efficacy in
splice site alteration and disease modification in both animal and
human trials [18–20]. Our work demonstrates the use of
morpholino oligomers alters the splicing of VEGFR1 such that
production of soluble Flt-1 is favored both in vitro and in vivo.
Furthermore, we demonstrate the efficacy of increased sFlt-1
expression in treatment of aberrant blood vessel growth in ocular
and cancer disease models. Thus, morpholino technology holds
promise for use in the context of human disease.
Results
VEGFR1_MOe13 promotes a shift from membrane
VEGFR1 to soluble VEGFR1 in vitro
In order to demonstrate the utility of morpholino constructs for
modulating sFLT-1 expression, morpholino oligomers were de-
signed targeting the FLT-1 mRNA exon13-intron13 junction
(VEGFR1_MOe13) or intron13_exon14 junction (VEGFR1_
MOi13). The canonical Flt-1 gene consists of thirty exons in human
and mouse. Full-length mRNA from all exons produces mbFLT-1.
By contrast, sFLT-1 utilizes a polyadenylation site within intron13.
Therefore, interaction between the morpholino constructs and
VegfR1 pre-mRNA is predicted to influence the alternative splicing
event such that production of soluble FLT-1 is favored. To directly
measure the relationship between membrane bound and soluble
FLT-1 in the presence of VEGFR1_MOe13 and VEGFR1_
MOi13, human umbilical vein endothelial cells (HUVEC) were
electroporated with targeting or standard morpholino oligomers
designed against human VEGFR1. Using this technique MO
constructs were found to sufficiently access the nuclear compart-
ment (Fig. 1a). Forty-eight hours after electroporation, total RNA
was harvested and soluble VEGFR1 and membrane VEGFR1
mRNA expression was assessed using real-time PCR.We found that
VEGFR1_MOe13, VEGFR1_MOi13, and a combination of
a combination of one-half dose of both VEGFR1_MOe13 and
VEGFR1_MOi13 significantly decreased membrane VEGFR1
mRNA and increased soluble VEGFR1 mRNA (Fig. 1b–c;
Figure S1). To determine if the VEGFR1 morpholino constructs
also affected soluble FLT-1 expression at the protein level, soluble
VEGFR1 protein in HUVEC culture medium was measured by
ELISA in the presence or absence of the VEGFR1 morpholino
constructs or control mopholino. VEGFR1_MOe13 increased
soluble VEGFR1 protein production as compared with standard
morpholino or control PBS conditions (Fig. 1d). In contrast,
VEGFR1_MOi13 were less effective, whereas combined delivery of
both VEGFR1_MOi13 and VEGFR1_MOe13 showed interme-
diate response, possibly due to competitive interference or reduced
efficacy of one morpholino as compared with the other. Thus,
morpholino targeting of the FLT-1 mRNA exon13-intron13
junction using VEGFR1_MOe13 is most efficacious for increasing
sFLT-1 and decreasing mbFLT-1 expression in vitro.
To ensure that this effect was not cell line specific, we sought to
validate our findings in other cellular backgrounds. Although
soluble FLT-1 is predominantly a product of endothelial cells per
its role in angiogenesis, it is also expressed by a number of other
cell types including tumor cells [15,21–24]. Thus, we sought to
determine whether expression of the VEGFR1_MOe13 in MCF7
and MBA-MD-231 breast adenocarcinoma cells would increase
soluble FLT-1 levels. As demonstrated in figure 2, electroporation
of VEGFR1_MOe13 directed against the human FLT-1 tran-
script increases soluble FLT-1 RNA and decreases membrane
FLT-1 RNA in both adenocarcinoma lines (Fig. 2a–d).
VEGFR1_MOe13 increases sFlt/mFlt mRNA ratio in the
mouse retina and suppresses laser-induced choroidal
neovascularization volume in vivo
In order to directly test the efficacy of the VEGFR1_MOe13 for
both in vivo activity as well as predicted effect on the process of
angiogenesis we adopted the well established murine model of
laser-induced choroidal neovascularization which induces signifi-
cant CNV lesions 1 week after laser injury [25–26]. We
hypothesized that expression of VEGFR1_MOe13 in vivo would
both increase soluble Flt-1 levels and lead to suppression of laser-
induced CNV. To first evaluate the effectiveness of VEGFR1_
MOe13 to modulate sFlt-1 levels in vivo, we examined the sFlt/
mFlt mRNA ratio in the mouse retina 24 hours after injection with
PBS, vivo-standard_MO, or vivo-VEGFR1_MOe13 designed to
target murine sFlt-1 (the ‘‘vivo’’ denotes modification allowing
MO construct to enter cells in vivo as demonstrated [27]). We
found that intra-vitreol injection of vivo-VEGFR1_MOe13 leads
to a significant increase of sFlt/mFlt mRNA ratio as compared
with PBS or vivo-standard_MO injection (Fig. 3a). Thus,
VEGFR1_MOe13 expression is sufficient to increase soluble Flt-
1 expression in vivo.
To determine whether VEGFR1_MOe13 expression in vivo
could suppress development of CNV in the setting of laser insult,
vivo-VEGFR1_MOe13, vivo-standard_MO or PBS were injected
intra-vitreously on day 1 and day 4 after laser photocoagulation.
One week after laser photocoagulation, eyes were enucleated and
the degree of CNV volume was measured by confocal microscope
after isolectin GS-IB4 vasculature staining. CNV volumes were
quantified using confocal microscopy. Murine eyes treated with
intra-vitreal vivo-VEGFR1_MOe13 displayed a statistically sig-
nificant decrease in CNV volume as compared with eyes treated
with either vivo-standard morpholino or PBS controls (Fig. 3b–d).
sFLT-1 Moropholino Decreases Neovascularization
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Thus, intra-vitreol injection of vivo-VEGFR1_MOe13 leads to
increased levels of sFlt-1 and suppression of laser-induced CNV.
Short hairpin RNA-mediated sFlt-1 knock-down ‘‘rescues’’
the CNV phenotype in vivo
In order to demonstrate that the measured effect of reduced CNV
following intra-vitreol injection of VEGFR1_MOe13 was specific for
an increase in sFlt-1 expression, we knocked-down sFlt-1 expression
AAV2_shsFlt encoding short hairpin RNA(shRNA) targeting sFlt-1
mRNA (unpublished data; [10]). Intra-vitreol injections were
performed using PBS, AAV2_shNEG (non specific shRNA) or
AAV2_shsFlt (shRNA targeting sFlt-1) and laser photocoagulation
performed 2 weeks later. In a consistent fashion with prior studies, on
day 1 and 4 following photocoagulation PBS, vivo-standard_MO or
vivo-VEGFR1_MOe13 constructs were injected into pretreated eyes.
We hypothesized that if increased sFlt-1 was sufficient for suppression
of the laser-induced CNV phenotype, co-expression of AAV2_shR-
NA_sFlt would reverse this effect. In agreement with this hypothesis,
we observed that pre-treatment with AAV2_shsFlt results in reversal
of VEGFR1_MOe13-mediated CNV suppression (Fig. 4). Thus,
increased soluble Flt-1 expression is sufficient to at least partially
mediate CNV suppression in the setting of laser-induced injury.
Figure 1. VEGFR1_MOe13 localizes to the nucleus and increases sFLT-1 expression in human endothelial vein cells (HUVEC). (a)
Fluorescently tagged VEGFR1_MOe13 (F-MO) or standard morpholino (std-MO) were electroporated into HUVECs. After 48 hours fluorescence was
assessed using light microscopy. Colocalization with DAPI staining represents nuclear localization of morpholino constructs. HUVECs were
electroporated with VEGFR1_MOe13, VEGFR1_MOi13, a combination of VEGFR1_MOe13 and VEGFR1_MOi13, Standard_MO. All morpholino
sequences were designed to target the human VEGFR1 transcript. (b) mbFLT-1 mRNA (n= 6) or (c) sFLT-1 mRNA expression (n = 6) were assessed
using real time PCR. Values were normalized to GAPDH mRNA and normal HUVEC was used as 1.0. (d) sFLT protein expression in culture medium was
determined by ELISA (n = 3). Data shows sFLT protein at 96 h – 48 h. Error bar is S.E.M. Each p-value was calculated by two-tail student’s t-test against
normal HUVEC.
doi:10.1371/journal.pone.0033576.g001
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Treatment of established MBA-MD-231 human breast
adenocarcinoma xenograft tumors with VEGFR1_MOe13
results in tumor regression
In order to demonstrate that anti-angiogenic activity of the
VEGFR1_MOe13 construct is not limited to the ocular compart-
ment, we sought to measure its efficacy in the setting of malignancy-
associated neovascularization. Tumor vasculature is a rapidly
emerging therapeutic target. As such, this model represents an
attractive context in which to apply technologies designed to inhibit
neovascularization. Within the context of malignancy, breast
adenocarcinoma is known to demonstrate marked dependence on
VEGF signaling for sustained neovascularization and growth [28–
29]. In fact, VEGF inhibition has been shown to reduce tumor
growth in both the experimental as well as the clinical setting
[17,30]. We hypothesized that treatment of MBA-MD-231 human
breast adenocarcinoma xenograft tumors with vivo-VEGFR1_
MOe13 would result in increased levels of soluble Flt-1 and a
subsequent decrease in neovascularization and tumor regression.
To directly test this hypothesis, female nude mice were inoculated as
described. Xenografts were permitted to grow for 14 days. Tumors
were then directly injected with either murine vivo-VEGFR1_
MOe13 or vivo-standard morpholino. Injections and tumor volume
assessments were performed bi-weekly for a duration of 4 weeks. We
found that treatment of xenograft tumors with vivo-VEGFR1_
MOe13 led to tumor regression when compared with standard
morpholino treatment (p= 0.04) (Fig. 5a). Furthermore, murine
sFlt-1 mRNA transcript levels were increased and mbFlt-1 mRNA
levels decreased in treatment tumors at the conclusion of the 4 week
treatment period as compared with control tumors when assessed
using real-time PCR (Fig. 5b–c). Finally, to determine whether
vascular density was decreased in tumors treated with viv-
VEGFR1_MOe13 injection, tumor vasculature was stained with
GS-IB4 and vessel density quantified using fluorescence microscopy
following the 4 week treatment period. Tumors treated with the
vivo-VEGFR1_MOe13 construct demonstrated a statistically sig-
nificant decrease in vascular density (Fig. 5d). Interestingly, these
results were achieved using VEGFR1_MOe13 targeting the murine
Flt-1 transcript, while treatment with a VEGFR1_MOe13 construct
targeting human FLT-1 did not demonstrate tumor regression in
vivo (Figure S2). This may indicate that host vasculature is important
for tumor growth,, suggesting that human sFLT-1 produced by
tumor cells does not effectively inhibit murine VEGF signaling.
However, analysis of the human and murine morpholino sequences
demonstrates significant overlap between the murine morpholino
construct with the human VEGFR1 sequence. The same is not true
for the human morpholino with respect to the murine VEGFR1
mRNA sequence. Therefore, this cross-reactivity could account for
our findings as could overall decreased efficacy of the human
morpholino construct. The latter is unclear given the fact that in vitro
this sequence increases soluble FLT-1 very effectively. Further
studies are needed to fully understand this.
Figure 2. VEGFR1_MOe13 increases sFLT-1 and decreases mbFLT-1 mRNA in MCF-7 and MBA-MD-231 breast adenocarcinoma cell
lines. MCF7 or MBA-MD-231 human breast adenocarcinoma cells were electroporated with VEGFR1_MOe13 and (a; c) sFLT-1 and (b; d) mbFLT-1
mRNA levels assessed at 72 hours using real time PCR (n = 3). Data were normalized to GAPDH mRNA levels and normal MCF7 or MBA-MD-231 cells
were used a 1.0. *p,0.01.
doi:10.1371/journal.pone.0033576.g002
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Discussion
Neovascularization is a common pathological process under-
pinning numerous disease states. Elucidation of key molecular
mediators has allowed for the development of therapeutic
strategies targeting the underlying molecular processes. Soluble
Flt-1 first described in 1993, is an alternatively spliced form of the
Flt-1 gene [4–5]. The morpholino oligomer VEGFR1_MOe13 is
designed to target the Flt-1 mRNA exon13-intron13; therefore,
interaction between VEGFR1_MOe13 and VegfR1 pre-mRNA is
predicted to influence the alternative splicing event such that
production of soluble Flt-1 is promoted.
Herein we demonstrate that expression of VEGFR1_MOe13
both in vitro and in vivo results in elevated levels of soluble Flt-1 and
decreased membrane bound Flt-1. Furthermore, these data show
that VEGFR1_MOe13-mediated increase in soluble Flt-1 within
the retina can prevent choroidal neovascularization following laser
photocoagulation. Finally, our data indicate that this phenotype is
attributable to increased sFlt-1 expression as co-treatment with
sFlt-1-RNAi negates this effect. Thus, soluble Flt-1 expression is
both necessary and sufficient for suppression of laser-induced
CNV. Taken together these data indicate that modulation of
soluble Flt-1 expression in the clinical setting has potential
therapeutic value. This represents great promise when considering
the over 7 million patients in the US alone with non-exudative age
related macular degeneration (ARMD) currently ‘‘at risk’’ for
development of CNV.
Angiogenesis in the form of aberrant neovascularization is
fundamental to the pathophysiology of other disease states as well.
Notably, new blood vessel formation is absolutely required for
sustained solid tumor growth [7]. As noted, breast adenocarcino-
ma is dependent on sustained neovascularization both in animal
and human studies [28–29]. As a ‘‘proof of principle’’ for broad
Figure 3. VEGFR1_MOe13 inhibits laser-induced CNV in vivo. a. sFlt/mFlt mRNA ratio in the retina treated with PBS, Standard_MO and
VEGFR1_MOe13 (n = 4). Representative images of laser CNV injected with b PBS, c Standard_MO and d VEGFR1_MOe13 designed to target the murine
VEGFR1 transcript. e The averages of laser CNV volumes (n = 11–14). Error bar is S.E.M. p-values were calculated by two-tail student’s t test.
doi:10.1371/journal.pone.0033576.g003
Figure 4. RNAi targeting sFlt-1 rescues the neovascular
phenotype response to laser injury. Murine eyes were treated
with PBS, AAV2_shNEG or AAV2_shsFLT. After 2 weeks, laser photo-
coagulation was performed. On 1 day and 4 day after photocoagula-
tion, PBS Standard_MO or VEGFR1_MOe13 were injected. Error bar is
S.E.M. N = 9–15.
doi:10.1371/journal.pone.0033576.g004
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applicability of morpholino-mediated Flt-1 modulation in the
treatment of neovascular disease, we demonstrate that intra-
tumoral injection of VEGFR1_MOe13 leads to increased intra-
tumoral levels of sFlt-1 and decreased mbFlt-1.. Furthermore,
breast adenocarcinoma xenografts expressing elevated levels of
sFlt-1 demonstrate a blunted neovascular response and regress
once established as compared with control tumors. Thus,
modulation of soluble Flt-1 expression using morpholino technol-
ogy represents a therapeutic tool with broad applicability across a
spectrum of neovascular disease.
Taken together, these data indicate that morpholino expression
is a viable tool for modulating the expression of FLT-1, i.e., the
balance between membrane and soluble forms of this transcript. In
our system, these data indicate that morpholino interference at the
Flt-1 mRNA exon13-intron13 junction leads to the greatest
amount of soluble FLT1 production. The VEGFR1_MOe13
construct is effective in two independent disease models, choroidal
neovascularization and breast adenocarcinoma. In both, aberrant
vasculature and disease burden are reduced. Given the highly
divergent roles of FLT1 isoforms, morpholino oligos show promise
in a variety of physiologic settings and disease states to act as an
‘‘exogenous switch’’ to modulate angiogenesis.
These data demonstrate the efficacy of morpholino technology to
influence FLT-1 gene expression at the mRNA level both in vitro and
in vivo setting. Recent application of splice-blocking morpholinos in
the setting of DMD has demonstrated disease-modifying effects in
both animal and human trials [18–20]. Therefore, these constructs
hold promise as true ‘‘bench to bedside’’ tools. Within the setting
of neovascularization, use of morpholino technology represents
a shift from current therapies which are predominantly based
on monoclonal antibody approaches. The evolving potential for
morpholino technology to be targeted to areas of pathology
following systemic administration may lend this technology to
broader appeal and utility [31]. Additionally, combining morpho-
lino-mediated sFLT-1 modulation with other known anti-angio-
genic strategies is a promising area of investigation. For example,
Figure 5. Intra-tumoral VEGFR1_MOe13 injection results in regression of established MBA-MD-231 human breast adenocarcinoma
xenograft tumors and decreased tumor vascularity. a. MB-MDA-231 breast cancer cells were grown as xenografts in female nude mice for 2
weeks prior to beginning treatment with either a standard morpholino or VEGFR1_MOe13 designed to target the murine VEGFR1 transcript.
Morpholino treated tumors demonstrate size regression after a 4 week treatment course as demonstrated by volume change analysis of 5 individual
tumors within each treatment condition. p = 0.04 b–c. Following treatment course, RNA was extracted from xenograft tumors and soluble or
membrane bound Flt1 levels were measured using real-time RT-PCR. Error bars indicate variation between individual PCR reactions per tumor sample.
d. Following the treatment course, VEGFR1_MOe13 or standard morpholino xenograft tumors were sectioned and stained with isolectin as a measure
of vascularity. Individual bars represent sections analyzed thoughout each tumor sample.
doi:10.1371/journal.pone.0033576.g005
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morpholino-based inhibition of other angiogenic factors such as
FGF and PDGF remains an interesting question, as these factors
have been shown to promote intra-ocular neovascularization and
inhibition shown to reduce neovascular pathology [32–34].
Furthermore, synergy between these pathways has been shown to
promote tumor vascularity and metastasis in murine studies [35–
36]. Therefore, steric inhibition of splice sites required for proper
expression of these factors may represent yet another role for
morpholino technology in the treatment of neovascular disease.
Thus morpholino technology currently represents an effective
mechanism for treatment of neovascular pathology across a




In vivo morpholino constructs were designed to target murine
intron/exon 13 junction of the FLT-1 transcript denoted
VEGFR1_MOe13 and VEGFR1_MOi13. Constructs were
chemically modified such that they would easily diffuse to access
the intracellular compartment [27]. For use in xenograft assays,
VEGFR1_MOe13 morpholino constructs were suspended in
sterile PBS and used at a concentration of 400 ng/dose. Each
dose is equal to 50 ul total volume. A standard morpholino
targeting the murine beta-globin subunit2 was used as a control








AAV.shRNA.sFlt-1 was developed as previously described [11].
2.5610‘9 GC of AAV.shRNA.sFlt-1 were injected per experi-
mental condition.
Cell culture
Primary human umbilical vein endothelial cells (Lonza,
Walkersville, MD, USA) were cultured in EBM with EGM
SingleQuot Kit supplements and growth factors according to
the manufacturer’s instructions (Lonza, Walkersville, MD, USA).
To prevent loss of endothelial cell properties, cell cultures were
limited to passage number 4 to 7. MBA-MD-231 human breast
adenocarcinoma cells were obtained from the laboratory of Dr.
Bryan Welm MD at the Huntsman Cancer Institute, SLC, Utah
and maintained in RPMI culture medium containing 10% FBS.
MCF7 human breast adenocarcinoma cells were obtained for the
laboratory of Dr. Alana Welm PhD at the Huntsman Cancer
Institute, SLC, Utah and maintained per ATCC medium
recommendations.
Morpholino delivery to cultured cells and total RNA
extraction
10 ng of morpholinos were delivered to the nucleus by
nucleofection (Amaxa, Gaithersburg, MD, USA) using a Basic
Nucleofector Kit for Primary Mammalian Endothelial Cells
(Amaxa, Gaithersburg, MD, USA), program A-034 for HUVEC.
For one nucleofection, 16106 cells were used and plated on a 6-
well plate. After 2 days of culture, cells were trypsinized and total
RNA was extracted using a RNeasy mini kit (Qiagen, Valencia,
CA, USA)]. RNA concentrations were determined by 260 nm
absorption measured with a spectrophotometer.
Complementary DNA synthesis and quantification with
real-time PCR
Complementary DNA (cDNA) were synthesized from approx-
imately 400 ng total RNA using an Omniscript RT kit (Qiagen,
Valencia, CA, USA) and Oligo-dT primer (dT2) according to the
manufacturer’s instructions. Real-time PCR was performed using
a QuantiTect SYBR Green PCR Kit (Qiagen, Valencia, CA,
USA) and an aliquot 1:l of cDNA solution. The primer sequences





The combination of VEGFR1_F1 and R1 was designed to
detect the soluble form of human VEGFR1. The combination of
VEGFR1_F2 and R2 was designed to detect the membrane form
of human VEGFR1 .








The combination of VEGFR1_F1 and R1 was designed to
detect the soluble form of murine VEGFR1. The combination of
VEGFR1_F2 and R2 was designed to detect the membrane form
of murine VEGFR1 .
Real-time PCR conditions: 50uC for 2 minutes, 95uC for
10 minutes, followed by 40 cycles of 94uC for 15 seconds, 55uC
for 30 seconds, and 72uC for 30 seconds.
Laser induced choroidal neovascularization
Laser photocoagulation (532 nm, 150 mV, 100 ms, 100 mm;
NIDEK MC-4000) was performed on both eyes (2 to 5 spots per
eye) as described [24–25]. After enucleating the eyes, sclera/
choroid/RPE complex were fixed in 4% paraformaldehyde for
2 hours at 4uC. After blocking in 5% FBS/PBS with 0.02%
tritonX-100 and 2 mM MgCl2, samples were stained with 5 mg/
ml Alexa488 and Alexa546 conjugated isolectin GS-IB4 (Invitro-
gen Corporation, Carlsbad, USA) overnight. After washing the
samples were flat mounted on glass slides. CNV volume was
measured by scanning laser confocal microscopy (Olympus
America Inc., Center Valley, USA). These animal studies were
performed under IACUC protocol approval number 09-03005
approved by the Committee on the Ethics of Animal Experiments
at the University of Utah. All interventions were performed either
under sodium pentobarbital anesthesia or after animals were
humanely euthanized.
Xenograft analysis
36106 MBA-MD-231 human breast adenocarcinoma cells were
injected subcutaneously into the flanks of female nude mice.
Following a standardized 2 week inoculation period, xenograft
tumors were injected biweekly for a total duration of 4 weeks
with VEGFR1_MOe13 or standard morpholino control. These
constructs were prepared as detailed above. Tumor growth was
assessed using digital calipers with bi-weekly measurements
correlating with injection period. (Volume mm3=width26
length/2. These animal studies were performed under IACUC
protocol approval number 09-03005 approved by the Committee
on the Ethics of Animal Experiments at the University of Utah. All
sFLT-1 Moropholino Decreases Neovascularization
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33576
 
 
   86 
 
interventions were performed either under sodium pentobarbital
anesthesia or after animals were humanely euthanized.
Immunohistochemical anlaysis
Tumors were fixed in 4% paraformaldehyde for 2 h at 4 C,
cryoprotected in 15% sucrose and 30% sucrose, and then
embedded in OCT (Tissue-Tek, USA). Sections (12 um) were
cut and were incubated with isolectin (Griffonia simplicifolia,
Alexa Fluo568 conjugate 1:1000, Invitrogen Corporation, Carls-
bad, CA) overnight. Immunohistochemistry results were examined
using scanning laser confocal microscopy (Olympus, FLUO-
VIEW, FV1000, 206). These images were scored by Image-J
morphometry system using biometry scoring (Wayne Rasband).
After electroporation of F-MO(10 ul of 1 mM) or STD MO
into HUVECs, the cells were plated to 8 well glass slide (nunc,
Rochester, NY) coated with collagen. 24 hours later, the cells were
fixed with 4% parafolmaldehyde/PBS, stained with DAPI, and
observed with the Zeiss Axiovert 200 inverted fluorescence
microscope.
Statistical analysis
Data are presented as mean +/2SEM. Statistical analysis was
performed using student T test. A p-value 0.05 was considered
significant.
Supporting Information
Figure S1 The Soluble/Membrane FLT-1 ratio increases
following electroporation of VEGFR1_MOe13 into HUVEC.
HUVECs were electroporated with VEGFR1_MOe13, VEGFR1_
MOi13, a combination of VEGFR1_MOe13 and VEGFR1_
MOi13, Standard_MO. All morpholino sequences were designed
to target the human VEGFR1 transcript. mbFLT-1 mRNA and
sFLT-1 mRNA expression were assessed using real time PCR.
Values were normalized to GAPDH mRNA and normal HUVEC
was used as 1.0.
(TIF)
Figure S2 Intra-tumoral injection of VEGFR1_MOe13 target-
ing human FLT-1 does not induce xenograft tumor regression.
MB-MDA-231 breast cancer cells were grown as xenografts in
female nude mice for 2 weeks prior to beginning intra-tumoral
injection treatment with either a standard morpholino or
VEGFR1_MOe13 morpholino targeting the human FLT-1
transcript. Change in tumor volume was assessed following a 4
week treatment course. p= 0.3
(TIF)
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Diabetic retinopathy poses a significant challenge as the world experiences 
greater rates of diabetes. Current treatment options are helpful at slowing down the 
progression of retinopathy but do not stop or reverse its course (Campochiaro, Wykoff, 
Shapiro, Rubio, & Ehrlich, 2014). It is imperative that future therapeutics take advantage 
of the learned pathophysiology to harness parallel pathways and remedy this disease. The 
angiopoietin-Tie2 pathway is ripe for utilization and COMP-Ang1 is placed in the 
envious position of restoring homeostatic signaling DR (Lee et al., 2013). 
One of the first attempts at understanding DR was conducted by Cunha-Vaz four 
decades ago by focusing on whether the retina also enjoys the same privilege of a blood-
brain-barrier afforded to the brain and whether retinal diseases altered barrier function 
(Cunha-Vaz, 1966). Blood retinal barrier dysfunction was found to be a root cause of DR, 
which helped lead to the search for vascular permeability factors. Judah Folkman and 
Napoleon Ferrara helped usher in the modern era of anti-angiogenesis by discovering the 
hypothesized master angiogenic switch VEGF, also described as vascular permeability 
factor (Adamis et al., 1994; Leung, Cachianes, Kuang, Goeddel, & Ferrara, 1989). While 
their goal may have been directed at cancer therapy, anti-VEGF agents have played 
perhaps their most successful role in eye diseases including diabetic retinopathy.    
Tony Adamis helped push the newly discovered anti-VEGF therapies toward 
treating vascular diseases of the eye. Realizing that increased VEGF was merely a 
downstream effect due to vascular dysfunction, Adamis and colleagues tested the idea 
restoration of deficient Ang1 signaling could ameliorate some of the effects of DR 
(Joussen et al., 2002). However, progress was stalled as utilization of Ang1 proved to be 
too difficult for therapeutic use. Importantly, the critical role of leukocyte-mediated 
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damage in the diabetic retina was discovered and recognized as an important therapeutic 
target in DR (Adamis et al., 2001; Joussen et al., 2004).  
Despite the development of treatments for DR, revitalizing the dying retinal 
vasculature has remained an unrealized goal. Endothelial progenitor cell (EPC) therapy 
represents an exciting avenue to replenish damaged capillaries in diabetic retinopathy. 
However, circulating endothelial progenitor cells are damaged in diabetic patients, 
requiring either a treatment that can restore endogenous EPC function or transplantation 
of nondiabetic EPCs into patients with retinopathy (Afzal et al., 2007; Bhatwadekar, 
Shaw, & Grant, 2010). Alan Stitt’s group has developed a reliable way to harvest true 
EPCs called endothelial colony-forming cells (ECFCs), which have very low MHC 
expression, resulting in low immunogenicity that could work to its advantage in treating 
patients with DR (Medina, O'Neill, Humphreys, Gardiner, & Stitt, 2010a; Medina et al., 
2010b; Stitt et al., 2011).   
Additionally, gene therapy continues to gain traction in treating retinal disease 
(Al-Saikhan, 2013). The eye is uniquely situated among organs to be amenable to gene 
therapy in so much as it is relatively isolated from the rest of the body. Jean Bennett has 
been at the forefront in advancing gene therapy, and in particular AAV-mediated therapy 
of inherited retinal diseases (Bennett et al., 2012). Thanks to the pioneering work with 
congenital retinal degeneration, AAV is gaining acceptance as a safe and effective 
therapy (Maclachlan et al., 2011). We have been able to harness this knowledge and 
apply it to a chronic, noninherited disease. Combining gene therapy with therapeutics for 
chronic diseases, like diabetic retinopathy, will ease future burdens for both patients and 
providers by decreasing the amount of office visits and intraocular injections.  
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This project was a synthesis of the previous attempts to restore homeostasis in the 
diabetic retina. By utilizing COMP-Ang1, we have built on the work done by Adamis, 
which stalled due to inability of Ang1 to be used in therapeutic doses. We have treated a 
chronic disease whose pathology is influenced by deficient Ang1 signaling with a viral 
vector usually reserved for inherited genetic disorders. Lastly, we have shown that 
COMP-Ang1 enhances the abilities of ECFCs to incorporate into the diabetic retina, 
getting closer to the elusive goal of capillary revitalization.   
Improvements in this study, like every study, are needed to take this therapy to the 
clinic. Currently, we rely on mouse models of diabetes, which are limited in their ability 
to recapitulate advanced forms of the disease. While they do a remarkable job of 
imitating the early forms of diabetic retinopathy (as demonstrated in our data), they leave 
much to be desired in a model of proliferative retinopathy (Barber et al., 2005). This 
could be attributed to the duration required by diabetes to lead to severe pathology and 
that current animal models simply do not live long enough to develop the neovascular 
forms of the disease. Additionally, perhaps an as yet undiscovered physiological pathway 
is activated in humans as opposed to animals with diabetes. We have yet to address the 
important issue of turning off AAV2 gene therapy. While constitutive COMP-Ang1 is 
important for normal retinal homeostasis, we would ultimately like to have control of the 
AAV-product should the need arise to decrease the dose. These barriers will have to be 
addressed before this therapy is moved to the clinic.  
 This project represents a translatable therapeutic approach restoring a lost trophic 
factor, preserving remaining endothelial cells, and preventing neuronal dysfunction. Most 
excitingly, reversal of endothelial damage could be possible with a combination of 
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COMP-Ang1 and ECFCs. Future directions could look towards the effectiveness of 
COMP-Ang1 combined with current therapies (anti-VEGF, laser photocoagulation, and 
steroids) and experimental therapies (anti-Ang2, VE-PTP inhibitors) (Quaggin, 2012). 
Furthermore, future directions could help clarify the mechanisms by which COMP-Ang1 
exerts its effects in the retina (lowering oxidative stress, mechanisms of decreasing 
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COMP-ANG1 IN THE PROTECTION AGAINST CENTRAL  
 
RETINAL ARTERY OCCLUSION 
 
The following material represents preliminary data collected and presented as a 
grant. The data gathered show the effectiveness of COMP-Ang1 treating a chronic retinal 
ischemia (diabetic retinopathy) and invited us to attempt to treat a currently untreatable 
form of acute retinal ischemia, central retinal artery occlusion. While development of 
these studies is still ongoing, I have laid important groundwork and proof-of-concept 
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A.1 General background 
 
Central retinal artery occlusion (CRAO) is the ocular correlate of stroke and heart 
attack (Suri, Nasar, Hussein, Divani, & Qureshi, 2007); however, no therapy has proven 
beneficial and improvement is extremely rare (Atebara, Brown, & Cater, 1995). Hence, 
potential neuroprotective or neuroregenerative therapies an unmet medical need. 
The nervous and vascular systems develop in synchrony and share many receptors 
and signaling cascades in common, e.g., VEGF/VEGFR2 (Chen, Fu, Tung, & Ward, 
2009; Jones & Li, 2007). Angiopoietins represent another family of growth factors that 
may mediate effects in both vascular and nervous systems (Zacchigna, Ruiz de 
Almodovar, & Carmeliet, 2008).  Angiopoietin 1 (Ang1) is a pericyte-derived growth 
factor that increases blood vessel stabilization and survival via the Tie2 receptor (Ward & 
Lamanna, 2004). Moreover, Ang1 has neuroprotective effects (Papapetropoulos et al., 
1999), and can act on neuronal cells independent of Tie2, primarily via β-1 integrin 
(Dallabrida, Ismail, Oberle, Himes, & Rupnick, 2005; Valable et al., 2003). COMP-Ang1 
(a more soluble and potent recombinant form of Ang1) was shown to improve 
neurological deficits and increase number of endogenous neuronal progenitor cells 
(NPCs) in a rat model of cerebral stroke (Shin et al., 2010).   
The neuroregenerative potential of the retina may lie with the Muller glia, whose 
position spanning all retinal layers has posited them as a target for healing potential 
within the retina. Certain subsets of Muller glia have been shown to undergo neurogenic 
changes when the retina is damaged (Chen et al., 2009). Muller glia in mice can even 
respond to damage by re-entering the cell cycle, expressing key neural progenitor 
markers, and producing new neurons (Karl et al., 2008). 
   97 
 
Our central hypothesis is that COMP-Ang1 promotes neuronal survival in CRAO 
by 1) neuroprotection, or 2) neuroregeneration.  This proposal will determine whether 
COMP-Ang1 promotes retinal ganglion cell survival through β-1 integrin and/or has the 
capacity to induce Muller glial neurogenesis. Our preliminary data demonstrate a role for 
COMP-Ang1 in neuroprotection via increasing neuroglobin in a β-1 integrin dependent 
manner and neuroregeneration by increasing neural progenitor markers in Muller glia 
after CRAO. 
This project explores the potential mechanisms of adult retinal neuroprotection, 
neurogenesis, and the interplay between vascular signaling molecules and neurogenesis. 
This project will open a new avenue into retinal preserving-therapies.  
While CRAO affects only a small population, exploring the field of retinal 
neurogenesis has the potential to reverse millions of cases of blindness including 
glaucoma, diabetic retinopathy, retinitis pigmentosa, with further implication in the CNS. 
 
 
A.2 Preliminary data 
C57/Bl6 mice were pretreated with intravitreal injection of adeno-associated virus 
serotype 2 (AAV2) that expressed either COMP-Ang1 or control (GFP). Three weeks 
after initial pretreatment CRAO was induced in after Rose Bengal tail vein injection and 
excitation with laser. Confirmation of occlusion was done with fluorescein angiography 
(Figure A.1a). Inner retinal cell layer loss was found three weeks after CRAO, but was 
prevented with COMP-Ang1 (Figure A.1b). In the COMP-Ang1 pretreated retinas, not 
only was histology preserved, but ganglion cell marker TuJ1 and progenitor marker Sox2 
was increased (Figure A.2a,b). In addition to structural preservation, mice pretreated with 
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Figure A.1. Fluorescein angiography confirms presence of CRAO two hours after 
laser treatment (a). Histology confirms loss of inner retinal layers in the 
AAV2.GFP pretreated mice, which was prevented with AAV2.COMP-Ang1 (b). 
  
COMP-Ang1 recovered visual acuity and electrical responsiveness better than control 
treated mice (Figure A.3a,b).  
To determine whether COMP-Ang1 could serve a protective role after CRAO, 
mice expressing TdTomato in the muller glia were given CRAO followed by intravitreal 
injection of COMP-Ang1 protein (as opposed to pretreatment with AAV2.COMP-Ang1 
before CRAO). These mice experienced increased neural progenitor markers (MCM6), 
markers colabeled with Muller glia, expressing TdTomato and increased proliferative 
markers (PCNA) in cells co-labeled with Sox2 compared to PBS treatment (Figure A.4). 
These preliminary data invite further investigation into the role of COMP-Ang1 after 
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Figure A.2 Retinal cross sections taken three weeks after CRAO show COMP-Ang1 
preserved the ganglion cell marker TuJ1, white (a) and neural progenitor marker 
Sox2, white (b). 
 CRAO. COMP-Ang1 increases neuroglobin in cell culture and mouse retina (Figure 
A.5a). The protective effects of COMP-Ang1 on a neuronal cell culture were dependent 
on beta-1 integrin (Figure A.5b). 
 
 
A.3 Experimental design 
Our preliminary experiments show that retinal neuronal structure and visual 
function are preserved by COMP-Ang1 therapy for CRAO. Retinal ganglion cells do not 
express Tie2 but do express beta-1 integrin, a pathway for direct neuroprotective effects.   
We treated W3 and BD-RGC mice, which express YFP in distinct subsets of 
retinal ganglion cells, with an intravitreal injections of COMP-Ang1 protein 
(angiopoietin-1 and PBS will serve as controls) two hours and one week after CRAO and  
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Figure A.3 Functional data showing COMP-Ang1 protects against prolonged 
visual tracking impairment (a) and ERG (b). 
tracked mice over three weeks. We measured the following indices relative to control: 
1. Retinal ganglion cell survival: We tracked YFP signal from RGCs before, and at 
day 0, 1, 3, 7, and 21 after CRAO using confocal scanning laser ophthalmoscopy 
(Spectralis, which can visualize YFP signal in the retina).  
2. Apoptosis: TUNEL, Fluorescent-annexin V (FLIVO, for in vivo tracking on 
Spectralis). 
3. Neuroglobin: assayed with Western blot and real-time qPCR.  
To determine if effects are due to the Tie2 pathway or β-1 integrin, we performed the 
same experiments in subgroups of mice treated with anti-Tie2 neutralizing antibody 
(blocking Ang1 signaling through Tie2) or anti-β-1 integrin antibody (which would block 
COMP signaling through β-1 integrin); controls included AAV2.GFP, PBS, or IgG 
control. 
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Figure A.4 Mice were treated after CRAO with COMP-Ang1 protein or PBS. 
COMP-Ang1 increased expression of MCM6 in muller glia (a) and Sox2 and PCNA 
colocalization (b). 
 
We expected that COMP-Ang1 increases retinal ganglion cell survival in a β-1 
integrin dependent manner. This would be manifest as persistence of YFP signal in mice 
and decreased apoptotic staining with a concomitant increase in neuroglobin. 
W3 and BD-RGC mice were selected as they are mouse strains with highest and 
least sensitivity to ischemic insult (personal communication from Dr. Ning Tian).  If they 
were found not suitable for any reason, four other mouse strains exist with YFP 
expression expressed selectively on other RGC subsets.  
Our preliminary data demonstrated exciting findings that COMP-Ang1 protein 
given as an intravitreal injection immediately after CRAO induced Muller cells to express 
markers of neural progenitor cell transformation (MCM6) and other retinal cells to 
express both proliferative (PCNA) and progenitor (Sox2) markers. Defining whether this 
is true entailed elucidation of several transcriptional and protein expression events,  
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Figure A.5 COMP-Ang1 protein increased neuroglobin in cell culture and mouse 
retina (a). COMP-Ang1 promotes neuronal survival in a β-1 integrin dependent 
manner (b). 
specifically for markers of transformation into neural progenitor phenotype, proliferation, 
cell type differentiation, and connectivity.  
In vitro, MIO-M1 cells (the only established line of Muller cells) were exposed to 
acute hypoxia (using the EVOS cell culture incubator), and then treated with COMP- 
Ang1, COMP-Ang1+sTie2r, COMP-Ang1+anti- β-1 integrin antibody (or IgG control), 
or PBS. We then assessed RNA expression of neural progenitor markers (Sox2, Shh, 
Notch, Wnt, Hes1) by RT-PCR, and protein markers of phenotypic status (MCM6, TuJ1, 
Sox9) by immunocytochemistry. Other controls included COMP-Ang1 without hypoxia 
and hypoxic muller glia without COMP-Ang1.   
In vivo, mice were treated with intravitreal injections of COMP-Ang1 two hours after 
and one week after CRAO; recombinant angiopoietin-1 and PBS injections served as 
controls. We then assessed the following indices relative to control: 
1. Retinal neurogenesis. Retinas taken from mice underwent: 
a. Cryosection: in situ hybridization to examine expression of neural 
progenitor markers (Sox2, Shh, Notch, Wnt, Hes1) and immunofluorescence 
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for markers of proliferation (PCNA), neural progenitor status (MCM6), 
ganglion cells (TuJ1), Muller cells (Sox9), and synapses (bassoon).  
b. Plastic embedding: for histologic staining (H&E, and Toluidine-Blue) as 
well as computational molecular phenotyping (CMP).   
We predicted that COMP-Ang1 would induce Shh, Wnt, Notch, Sox2, and increase 
synapse formation compared to PBS. We predicted that COMP-Ang1 would promote 
neurogenesis from Muller glia resulting in increased number of ganglion cells (CMP). 
Rose Bengal-induced central retinal artery occlusion can be altered to provide varying 
degrees of severity of occlusion. We have previously determined settings, which allow 
for severe occlusion (described above). Alternatively, we could have produced a less 
severe occlusion (by decreasing the power and number of pulses given per eye), which 
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